POPULARITY
2 episodes with young investigator
2 episodes with young investigator
2 episodes with young investigator
3 episodes with young investigator
Send us a textDr Chris McCarthy is a Clinical Fellow (Associate Professor) at Manchester School of Physiotherapy. He researches musculoskeletal interventions including exercise in long-term conditions and manual therapy. Prior to this he was a Consultant Physiotherapist at Imperial College Healthcare NHS Trust, St Mary's Hospital Paddington, London. After qualifying as a Physiotherapist in 1989 he undertook post-graduate training in Biomechanics and Manipulative therapy at Strathclyde and Coventry Universities before undertaking a PhD degree in rehabilitation within the faculty of Medicine at Manchester University. He was awarded a “Young Investigator of the Year” award in 2001, for his PhD studies, by the British Society of Rheumatologists.Chris has published over 60 peer reviewed papers on musculoskeletal rehabilitation and diagnosis and spoken at over 50 conferences. He has taught internationally on Manual Therapy, specifically on Combined Movement Theory, and lectures on five of the Masters courses in Manual Therapy in the UK. He is a member of the international advisory board for Manual Therapy journal and regularly reviews and publishes papers in the academic field of Manual Therapy. In this (at times clinical) conversation with Andrew Cox | Joint Dynamics he discusses his life's work, his PhD, some of the controversy surrounding hands on musculoskeletal therapy, and he shares his dream for best practice in the ever evolving field of health care and performance enhancementShow sponsor is Muvitality Medicinal Mushrooms for modern day health and wellness | Mu …Go to muvitality.com and use the code JD10 to receive a 10% discount on your purchase of Mu Functional mushrooms such as Lions Mane, Cordyceps, Chaga, Reishi, and Turkey tail functional mushroomsEnjoyHere are some useful links for this podcastLinked In - https://www.linkedin.com/in/combinedmovements/?originalSubdomain=ukCombined Movement Theory - https://images.app.goo.gl/awnrWEDA4repUc3W6Relevant episodesEpisode 120 - Your morning erections link to heart disease with Colin Symmonds https://podcasts.apple.com/us/podcast/episode-120-your-morning-erections-link-to-heart-disease/id1527374894?i=1000692986665Episode 107 - Father of Function Gary Gray https://podcasts.apple.com/us/podcast/episode-107-father-of-function-gary-gray-of/id1527374894?i=1000665866997JOINT DYNAMICS links:Joint Dynamics Facebook - https://www.facebook.com/JointDynamicsHongKong/Joint Dynamics Instagram -https://www.instagram.com/jointdynamics/Joint Dynamics Youtube - https://www.youtube.com/channel/UCRQZplKxZMSvtc6LxM5WckwJoint Dynamics Website - www.jointdynamics.com.hkHost - Andrew Cox -
Join Dr. Andy Cutler as he talks with the co-author of the winning poster from the 2023 NEI Congress Young Investigator Poster Competition, Dr. Richard Price. They discuss the objectives, design, and key findings of the poster titled, “Improved Mood and Weight Gain Mitigation Following Switch from Aripiprazole to Cariprazine.” They also discuss the potential implications of these findings and applications of cariprazine in psychiatry. Dr. Richard Price is an Assistant Professor of Clinical Psychiatry at Weill Cornell Medical College. Maxwell Zachary Price, the lead author of the winning poster, is a medical student at Hackensack Meridian School of Medicine. See the winning poster here. Learn about upcoming NEI Meetings at https://nei.global/meetings
Welcome to Episode 067 of the Beyond the Diagnosis Podcast. In this episode we're diving into the innovative Young Investigator initiatives within the Histiocyte Society, spotlighting the newly formed Young Investigator and Social Media committees. We explore their goals and strategies, highlighting how these efforts are cultivating the next generation of leaders and researchers in the world of histiocytosis. Join us as we discuss the exciting developments and the impact these committees are making on the future of the Society. Let us know what you think! Leave us a review, drop us a comment or share an idea for a future podcast with us at podcast@histio.org. Take a screenshot and tag us @histiocytosis_association on Instagram. We'd love to hear your feedback! Be sure to subscribe so you can be notified the moment a new episode of Beyond the Diagnosis is released. We would love it if you would consider supporting this podcast financially so we can continue to bring you relevant and timely information while on your histio journey. To learn more visit https://podcasters.spotify.com/pod/show/histio/support Resources mentioned in the podcast: Overview of the Histiocyte Society Strategic Plan: https://histiocytesociety.org/Strategic-Plan Follow the Histiocyte Society on social media: Twitter/X: @HistiocyteSoc LinkedIn: https://www.linkedin.com/company/histiocyte-society/ Follow the Histiocytosis Association on social media: Facebook: https://www.facebook.com/histio Twitter: @histiocytosis Instagram: histiocytosis_association YouTube: https://www.youtube.com/@Histiocytosis Music: “Heroes” by Noah Smith --- Support this podcast: https://podcasters.spotify.com/pod/show/histio/support
My guest today is Jeff Karp, a Canadian biomedical engineer working as a Professor of Medicine at Harvard Medical School, Brigham and Women's Hospital, and the principal faculty at the Harvard Stem Cell Institute and Affiliate Faculty at the Massachusetts Institute of Technology through the Harvard–MIT Division of Health Sciences and Technology. In 2008, he was listed as one of the top innovators. In 2011, he received Young Investigator award from the Society for Biomaterials, and the Champion in Health Care Innovation. The topic is his book LIT: Life Ignition Tools: Use Nature's Playbook to Energize Your Brain, Spark Ideas, and Ignite Action. In this episode of Trend Following Radio we discuss: Personal growth and overcoming obstacles Brain's ability to adapt and learn, particularly in individuals with learning differences Connection between physical activity, brain function, and emotional well-being Activation energy in achieving goals Incremental progress Importance of patterns and habits Neurodiversity and curiosity Dealing with failure and maximizing momentum Jump in! --- I'm MICHAEL COVEL, the host of TREND FOLLOWING RADIO, and I'm proud to have delivered 10+ million podcast listens since 2012. Investments, economics, psychology, politics, decision-making, human behavior, entrepreneurship and trend following are all passionately explored and debated on my show. To start? I'd like to give you a great piece of advice you can use in your life and trading journey… cut your losses! You will find much more about that philosophy here: https://www.trendfollowing.com/trend/ You can watch a free video here: https://www.trendfollowing.com/video/ Can't get enough of this episode? You can choose from my thousand plus episodes here: https://www.trendfollowing.com/podcast My social media platforms: Twitter: @covel Facebook: @trendfollowing LinkedIn: @covel Instagram: @mikecovel Hope you enjoy my never-ending podcast conversation!
My guest today is Jeff Karp, a Canadian biomedical engineer working as a Professor of Medicine at Harvard Medical School, Brigham and Women's Hospital, and the principal faculty at the Harvard Stem Cell Institute and Affiliate Faculty at the Massachusetts Institute of Technology through the Harvard–MIT Division of Health Sciences and Technology. In 2008, he was listed as one of the top innovators. In 2011, he received Young Investigator award from the Society for Biomaterials, and the Champion in Health Care Innovation. The topic is his book LIT: Life Ignition Tools: Use Nature's Playbook to Energize Your Brain, Spark Ideas, and Ignite Action. In this episode of Trend Following Radio we discuss: Personal growth and overcoming obstacles Brain's ability to adapt and learn, particularly in individuals with learning differences Connection between physical activity, brain function, and emotional well-being Activation energy in achieving goals Incremental progress Importance of patterns and habits Neurodiversity and curiosity Dealing with failure and maximizing momentum Jump in! --- I'm MICHAEL COVEL, the host of TREND FOLLOWING RADIO, and I'm proud to have delivered 10+ million podcast listens since 2012. Investments, economics, psychology, politics, decision-making, human behavior, entrepreneurship and trend following are all passionately explored and debated on my show. To start? I'd like to give you a great piece of advice you can use in your life and trading journey… cut your losses! You will find much more about that philosophy here: https://www.trendfollowing.com/trend/ You can watch a free video here: https://www.trendfollowing.com/video/ Can't get enough of this episode? You can choose from my thousand plus episodes here: https://www.trendfollowing.com/podcast My social media platforms: Twitter: @covel Facebook: @trendfollowing LinkedIn: @covel Instagram: @mikecovel Hope you enjoy my never-ending podcast conversation!
Sabaidee and hello! Welcome to another episode of Thip Khao Talk Podcast. Alex Hiniker, Legacies of War Board Chair Emeritus, sits down with our good friend, Dr. Erin Lin, to discuss her upcoming book 'When The Bombs Stopped'. Dr. Lin specializes in the study of war's long-term effects on human and economic development, both in Cambodia and more globally. One of the things that she seeks to do in her research and writing is to recover a more dynamic appreciation of the historical processes that shape development, by integrating personal interviews and on-the-ground fieldwork with archival data. She's also interested in exploring multidisciplinary approaches to answer key questions in political science. Her major research topics include aerial bombings, unexploded ordnance, and rural poverty. Within these themes, she investigates farmer behavior, gender norms, and policy effectiveness. Beyond these social-science themes, she has a deep interest in heavy metal contamination in soil systems and image processing. Her work incorporates techniques from computer science, machine learning, soil science, economics, and anthropology, and has been cited by The Economist, Gizmodo, Fox News, and The Cambodia Daily, among other media outlets. She's served on the Mines Advisory Group board of directors since 2021, and in 2022 was named a Young Investigator by the Air Force Office of Scientific Research, Theme song by Lao Jazzanova Learn more about Dr. Erin Lin: https://www.erin-lin.com/ Learn more about Legacies of War: https://www.legaciesofwar.org/
Fan Yang, PhD is an Associate Professor at Stanford University with joint appointments in the Departments of Orthopaedic Surgery and Bioengineering joins OsteoBites to discuss her work on tissue engineering strategies for elucidating OS biology and drug discovery.Fan Yang, PhD is the founder and Director of Stanford Stem Cells and Biomaterials Engineering Laboratory, and also Co-director of Stanford NIH Biotechnology Training Program. Her research seeks to develop hydrogels with unique micro- and nano- scale properties to promote stem cell differentiation, tissue regeneration and immunomodulation, with a focus on musculoskeletal diseases. Her lab also harnesses biomaterials to create 3D cancer models with in vivo-mimicking phenotype and drug responses. Such 3D models could enable discovering novel druggable targets that would otherwise be missed using conventional 2D culture, and enable high-throughput drug screening with reduced cost and time than animal models. Prior to joining Stanford, Dr. Yang received her Ph.D. in Biomedical Engineering from Johns Hopkins University, and then completed a postdoctoral fellowship at MIT under Prof. Robert Langer. In recognition of her innovation, she has been recognized by numerous awards including Fellow of American Institute for Medical and Biological Engineering, MIT TR35 Global list honoree, National Science Foundation CAREER award, Young Investigator Award from Society for Biomaterials, Biomaterials Science Lectureship Award, Young Investigator award from Alliance for Cancer and Gene Therapy, Ellen Weaver Award by the Association for Women in Science, Baxter Faculty Scholar Award, the McCormick Faculty Award, Stanford Asian American Faculty Award, and the Basil O'Connor Starter Scholar Research Award, etc.
Did you know that there are more than 10,000 rare diseases in the United States? So, what is a rare disease? Meet Rob Long who survived a very rare aggressive form of brain cancer, called anaplastic astrocytoma. When diagnosed, Rob was well on his way to securing a professional football career. He had been an All American punter for Syracuse University until he had to undergo brain surgery in his senior year. He was given a slim chance of surviving for more than a few months. 13 years later Rob and I got to meet and you get to hear our conversation. After a year of chemo and radiation therapy Rob recognized that he was not going to have a football career. However, as you will hear, football was an integral part of his healing. Today Rob is the executive director of Uplifting Athletes, an organization that combines sports with various projects to raise funding on research concerning rare diseases. This conversation is for me one of the most fascinating and, yes, uplifting ones I have had the pleasure to host. I hope you find it worth your time. About the Guest: Rob Long, Executive Director of Uplifting Athletes A suburban Philadelphia native, Rob is a former All-American punter at Syracuse and has lived the rare disease journey. In December of 2010, late in his senior season, Rob was diagnosed with anaplastic astrocytoma, a rare and aggressive form of brain cancer. His prognosis at the time was less than encouraging, and his surgery, recovery, and treatment took 16 months. Prior to his diagnosis, Rob was on a path to the NFL as a punter, but that opportunity was lost by the time he was healthy enough to train again. A graduate of Syracuse University, Rob pursued a Masters in New Media Management from the SI Newhouse School of Public Communications. He also received a BS from the Martin J. Whitman School of Management. Rob played football all four years for the Orange and was voted team captain by his teammates his final two seasons. He became the second Executive Director of Uplifting Athletes at the end of 2018. Prior to taking over as the Executive Director, Rob served as Uplifting Athletes' Director of Rare Disease Engagement for nearly two years. Rob has a steadfast commitment and connection to the rare disease community as a rare brain cancer survivor. As a former star college football student-athlete, his passion and drive to advance the mission of Uplifting Athletes is inspirational. Rob and his wife, Irie, reside in suburban Philadelphia with their dogs Winston and Rocket. Ways to connect with Rob: Twitter: https://twitter.com/roblong47 LinkedIn: https://www.linkedin.com/in/roblong47/ Instagram: https://www.instagram.com/roblong47/ Uplifting Athletes' Important Links: Website: https://upliftingathletes.org/ Twitter: https://twitter.com/UpliftingAth LinkedIn: https://www.linkedin.com/company/3007008/ Facebook: https://www.facebook.com/upliftingathletes Instagram: https://instagram.com/upliftingathletes YouTube: https://www.youtube.com/upliftingathletes Donation: https://upliftingathletes.org/donate About the Host: Michael Hingson is a New York Times best-selling author, international lecturer, and Chief Vision Officer for accessiBe. Michael, blind since birth, survived the 9/11 attacks with the help of his guide dog Roselle. This story is the subject of his best-selling book, Thunder Dog. Michael gives over 100 presentations around the world each year speaking to influential groups such as Exxon Mobile, AT&T, Federal Express, Scripps College, Rutgers University, Children's Hospital, and the American Red Cross just to name a few. He is Ambassador for the National Braille Literacy Campaign for the National Federation of the Blind and also serves as Ambassador for the American Humane Association's 2012 Hero Dog Awards. https://michaelhingson.com https://www.facebook.com/michael.hingson.author.speaker/ https://twitter.com/mhingson https://www.youtube.com/user/mhingson https://www.linkedin.com/in/michaelhingson/ accessiBe Links https://accessibe.com/ https://www.youtube.com/c/accessiBe https://www.linkedin.com/company/accessibe/mycompany/ https://www.facebook.com/accessibe/ Thanks for listening! Thanks so much for listening to our podcast! If you enjoyed this episode and think that others could benefit from listening, please share it using the social media buttons on this page. Do you have some feedback or questions about this episode? Leave a comment in the section below! Subscribe to the podcast If you would like to get automatic updates of new podcast episodes, you can subscribe to the podcast on Apple Podcasts or Stitcher. You can also subscribe in your favorite podcast app. Leave us an Apple Podcasts review Ratings and reviews from our listeners are extremely valuable to us and greatly appreciated. They help our podcast rank higher on Apple Podcasts, which exposes our show to more awesome listeners like you. If you have a minute, please leave an honest review on Apple Podcasts. Transcription Notes **Michael Hingson ** 00:00 Access Cast and accessiBe Initiative presents Unstoppable Mindset. The podcast where inclusion, diversity and the unexpected meet. Hi, I'm Michael Hingson, Chief Vision Officer for accessiBe and the author of the number one New York Times bestselling book, Thunder dog, the story of a blind man, his guide dog and the triumph of trust. Thanks for joining me on my podcast as we explore our own blinding fears of inclusion unacceptance and our resistance to change. We will discover the idea that no matter the situation, or the people we encounter, our own fears, and prejudices often are our strongest barriers to moving forward. The unstoppable mindset podcast is sponsored by accessiBe, that's a c c e s s i capital B e. Visit www.accessibe.com to learn how you can make your website accessible for persons with disabilities. And to help make the internet fully inclusive by the year 2025. Glad you dropped by we're happy to meet you and to have you here with us. **Michael Hingson ** 01:21 Well, Hi, and welcome once again to unstoppable mindset. I am your host, Mike Hingson. We are recording this in the summer of 2023. And we were just comparing notes. Our guest Rob Long is just outside Philadelphia. And one of the folks that he works with Valerie is up in Connecticut where it's over 90 today. And Rob and I probably are around the same temperature. It's about 82 or 83 here, but last week, it was over 100. And in fact for most of July, it was over 100 out here in Victorville. So go figure. But we all cope. And we all get along and do what we need to do. So Rob is the executive director of uplifting athletes, and he's going to tell us about that as we move forward. Rob, among other things, is a person who has had to deal with a rare disease. And again, I'm going to leave most of that for him to talk about, but he's an inspiration. And I'm really honored to have him on unstoppable mindset. He is another one of the folks who got introduced to us by our nonprofit partner manager, Sheldon Lewis, who got interviewed quite a while ago on this on this podcast. Well Rob, so welcome to unstoppable mindset. We're really glad you're here. **Rob Long ** 02:39 Thank you so much for having me, Mike. I'm thrilled and honored to have the opportunity to to join. **Michael Hingson ** 02:46 Well, why don't we start kind of where I love to usually start in this hearing about the early Rob, you know, growing up and some of that kind of stuff. **Rob Long ** 02:55 Sounds good. So probably go back. Gosh, back about 15 years ago, I was graduating high school outside Philadelphia and was fortunate to have received a full scholarship to play football at Syracuse University. I was a punter and kicker and was thrilled at the opportunity to play division one sports and really just got up on campus and I fell in love with with the university and playing football I had so much fun and I met so many great teammates that I still keep in touch with today. As I ventured through my college career, I was fortunate to have a really good career at Syracuse and was a freshman all American my first year and started to really I think capture some some intention from NFL scouts. And so by the time my senior year was starting, I was a captain my junior year I was elected a captain by my teammates my senior year as well. And going into my senior year, I pretty much just was focused on putting the football and doing what I needed to do and I would end up playing in the NFL. And you know, my biggest concern was which of the 32 teams were going to draft me and went in senior year and pretty much from the jump. Things did not go quite as I had expected. By the time my senior year was wrapping up, I still was having a pretty good year by regular standards on the field, but I knew there was something that was not quite right and Thanksgiving morning of 2010 I woke up was extremely sick and just kept throwing up and couldn't figure out what was happening. And you really just don't know how to describe it other than, like, I couldn't stop vomiting for two hours, two plus hours. Finally had stopped and made it down to the football facility, talk to the doctors, and I said, Hey, like, something's wrong, I, you know, I don't feel well. And they tried to give me some Pepto Bismol and pretzel sticks. And I threw those up as well. And so they kind of just didn't know what to do. I kind of hung around the facility. And as time passed, I, you know, started to feel a little bit better as the day went on. And, you know, pretty much by the end of the day, I kind of was like, Alright, I don't know what that was all about. And that was a Thursday. Two days later, I played my final college game against Boston College at home against Syracuse. And it was during that game, where I really started to feel the physical effects of what was happening to me, I, by the time I was punting, I had no idea when I dropped the ball out of my hand if it was going to hit my foot. And so really started to show on the field that something wasn't going quite right. So went back to the doctor, the team trainers after the game. And they said, We're going to make an appointment with team doctor. So I met with the team doctor, and he said, we're just going to start to try and rule some things out, sent me for an MRI of my brain. And it was December 2 2010. And I remember kind of joking with my mom before going into the MRI filling out the paperwork was my first time ever filling out medical paperwork and all those kinds of things. And went in had the MRI and about five minutes into the MRI of my brain, the radiate, radiologist stopped the machine and she came out and choose white as a ghost. And she said, hey, everything's fine. And she's speaking very fast, he was very pale, and said, we just need to run some more tests. And so they ran some more tests had a longer MRI gave me contrast, I all these things that I would later come to find out, you know, things weren't fine. And that's not normal procedure for somebody that, you know, has a normal brain scan. And so I remember walking out of the MRI room, and, you know, she was kept talking to her telling me stories trying to comfort me, but the whole time, I had no idea what was wrong or what was happening. And so she sent me out and just said, you know, good luck with everything. And I got back to the football facility. And that evening, met with the team doctor to have the MRI read and walked into the training room and the entire training staff was there. All of the team doctors, a few of my coaches were there. And generally that meant that a player had a season ending injury. And so I walked in and made it kind of a joke at the time. I was like, Oh, this must not be good. And nobody thought that was funny. So kind of realized that I was probably in trouble at that point. And sat down and the team doctor said you have a large growth in your brain. And you can see a specialist first thing in the morning. And, yeah, so I had to, I called called home. I knew given my mom's family's history of cancer. You know, I didn't have the heart to tell her. So I call my dad and he was on his way into his, his job. He was working second shift at the time. And he said, You know, I told him I had a growth in my brain and you're gonna see a specialist and say, I can't believe this. He said, I just left your mom at your aunt's house. Your hand Chrissy my mom's younger sister had been diagnosed with breast cancer earlier that day. So in the span of about eight hours, my mom found out that her youngest sister had breast cancer and that her only son had a brain tumor. So it was a it was a tough one for us at that time. **Michael Hingson ** 09:26 Needless to say, yeah. So what did they finally diagnosed he was having. **Rob Long ** 09:33 So after I got I saw the specialist the next day, I walked in and on my on the screen was my MRI and I had never seen a brain MRI before and there was a large white mass that took up a quarter of my brain. And then neurologists that basically said that's not supposed to be there. So they flew me home to Philadelphia And that's four days later, I met with a team of surgeons at Thomas Jefferson University Hospital in Philadelphia. I had spent my 22nd birthday getting prepped for brain surgery on December 13 of 2010. The next day I had brain surgery, and then six days later, I went back to the hospital to get the pathology report. They diagnosed me with a grade three anaplastic astrocytoma it is of the glioma family. So if you familiar with a glioblastoma, my type of tumor thigh my diagnosis, the five year survival rate was 15%. And the doctors told my parents at that point, probably had about 36 months to live. **Michael Hingson ** 10:48 Wow. And obviously, that didn't help the football career. And so that meant a lot of changes. But somewhere along the line, you obviously did something, right, because it's now been more than 36 months. It has. **Rob Long ** 11:08 Yeah, it's, we're over 12 and a half years now, believe it or not, I've been incredibly lucky. And so after I got my diagnosis, essentially went to went back to the doctors, and they gave him my options. And they said, there's a chemotherapy that you can take, it is the first first chemotherapy of its kind that has been FDA approved to penetrate the blood brain barrier. And along with that, I did 36 rounds of whole brain radiation. So they pretty much provided my life limit of radiation in about six and a half weeks, or about six weeks, and did chemotherapy every single day for for 30 days during that or for six weeks during that radiation period. And then took a month off and did another 12 months of chemotherapy, which are 28 day cycles. So go in the worst part of all of this was really the mental challenge that it presented, especially going through the 12 months of chemotherapy, because it was 28 day cycles. So I would spend 23 days preparing for five days of chemotherapy, and then I'd spend the next three weeks trying to gain all the weight back that I lost, trying to eat whatever I could to gain weight, knowing that I would lose about 15 pounds, going through my week of of chemo and be sick and not be able to eat certain things. And so think it was, you know, the definition of insanity, doing the same thing and expecting different results. Right. And it was that was my life for over a year. And it really took a mental and emotional toll over time. **Michael Hingson ** 13:17 Certainly that makes a lot of sense. I can kind of understand it. But at the same time, what were you thinking that got you through all of that? Or were were you just kind of maintaining at the time? Or did you have any other kinds of thoughts that that really helped drive you through it? Yeah, **Rob Long ** 13:34 though, one thing that got me going every single day was that I refuse to let this diagnosis be the thing that was the end of my life. I didn't want it to kill me. I didn't want my parents to have to deal with that. I wanted to play football. I wanted to end my football career on my terms, not because I was diagnosed with this, this disease and that's what I did every single day that I could I went to the gym, even days where I couldn't lift because my my blood cells weren't very Cooper ating fast enough, I would at least just go and show up and hang out and it was just a part of my routine every single day. You know, when I was going through chemo and radiation, I'd wake up I'd do my chemo first thing. I'd go to the hospital, I would do radiation. I'd come home from that. And pretty much go right to the gym and then take a nap eat dinner. And that was my life. And that was what I did. And it was the people that I saw every day. It was the the drive that I had that I wanted to. I wanted to get better. I wanted to play football in the NFL. That was my that was my dream and I wanted to do whatever it could take to make that happen. **Michael Hingson ** 15:00 So football really, in every sense of the word kept you going. And the fact that you had developed such a team spirit and working with a team and so on, were the people around you at the gym and all that pretty supportive, how to how did they all react to all of this? **Rob Long ** 15:15 They were unbelievable. I mean, I don't know. And they're just there. They're incredible. And I think the most important thing for me was that they saw me every day, they knew why I was there. And they just treated me like, I was anybody else that came to the gym and was just trying to work out and to get better. It wasn't about my cancer, we didn't talk about it every day, probably rarely talked about it. But talked about everything else that was happening in the world. And I think that sense of, of normalcy was what I was after, because I had no control over anything at that point. And so I was just trying to seek some level of consistency. And that's what I found. By working out by going to the field and putting footballs, that was the one thing that, you know, I knew I could put effort in and get reward out of and, you know, my health was, more or less not in my hands, or not as nearly as much in my hands as I would have wished it was. At the **Michael Hingson ** 16:29 same time, though. While you didn't have any real control over a lot of that, as we often talk about here on unstoppable mindset where you did have control over it was how you dealt with it. And you clearly did you develop the mindset and you stuck to it, and you developed an attitude. And you decided that you were gonna do everything you could to, to continue to grow and move forward, which had to be certainly a challenge. And a lot of things happen along the way that could try to topple that, but you did great. **Rob Long ** 17:01 Yeah, I, I don't know. Your where it all came from, I think there was a lot of lot of discipline and things that were instilled in me playing football at a high level, you know, that there's things that you need to take care of, in order to hold up your end of the bargain for your teammates and the people around you. And, you know, when I'm no longer on a team, and I'm going through treatment, like I still am going to do whatever I can to, to hold up my end of the bargain. And that means, you know, being there for my family and doing the things that I need to do. So that that I can be as helpful as I can. And I think for me, the the biggest piece is just knowing and I've learned this by going through what I've gone through is that at the end of the day, like you have to be the one that wants it and you need to be the one that is going to do it. And there is nobody there to tell me to go pump footballs, there's nobody there to tell me to go to the gym each day. In fact, there's probably a few people telling me not to go to the gym each day. But it was something that it provided me something to do and something to look forward to. That was not revolving around my medical diagnosis. **Michael Hingson ** 18:26 Yeah, there are just some things you do have to do for yourself. Nobody can do them for you, which is what you clearly discovered and realized. And so you you moved ahead, where your coaches supportive you weren't back at Syracuse, needless to say, you were down in Philadelphia. So did you hear from them or your teammates? In even now today? Do you still hear from them at all? **Rob Long ** 18:48 Yeah, they're, they're unbelievable. And I think it's, you know, a huge part of of why I you know, and I know we haven't talked about yet but of why the why we do the work that we do with uplifting athletes. It's there's an unbelievable power in in sports. And there's a camaraderie that is built there is a it's a it's another family. It's a non blood related family that you develop. And it's an incredible, incredible feeling to have the support of so many people I remember after surgery after my diagnosis. It was the first time in my football career in four years at Syracuse, we'd made it to a bowl game and I think the first time in probably seven or eight years that Syracuse had been to a bowl game. And my senior year we got to a bowl game. And you know, my my senior class had been a big part of why we were in a bowl game that year and I had surgery 17 days before our bowl game, and my goal was to get to that bowl game regard Are those of us anything else and it was quite an adventure to get there. But I did get there. Despite a New York City Blizzard trying to prevent that from happening, I got to the ballgame. And I saw my teammates. And to this day, one of the best days of my life, I just saw every single one of them, they gave me a hug. They were joking around with me messing around with me. And again, it was, it wasn't about me, or what I had been through, it was just about being back with my brothers, with my friends, and coaches and, and the staff that supported me and continued to to this day or are, you know, a huge reason of why I'm able to be where I am. **Michael Hingson ** 20:43 And I could go back and research but at Syracuse when we did all right now we're talking. Who did you play? Kansas State? Ah, there you go. Yep. **Rob Long ** 20:55 Yeah, point an old Yankee Stadium or new Yankee Stadium, Yankee Yankee Stadium. So, yeah, it was an awesome experience. So **Michael Hingson ** 21:03 do you think you've been there helps the team and contributed? Maybe, how but it did. **Rob Long ** 21:11 It was. It was just I think they were all and, you know, understandably, so concerned about me. It all happened very quickly, right? Sure. We played your final game, I think November 28. And within five days, I had been told that I had, you know, a tumor. And within three weeks, I was told that I had a rare and aggressive form of cancer. So it all went very quickly. So I think for them to see me after hearing all this, because I was, you know, away from them. And I think for them to see me, even without my hair was still you know, good to know that for them that was you know, still operating and doing what I love to do. And **Michael Hingson ** 22:00 you inspired I will bet anything that if you ask them, they would tell you, you inspired which is which is cool. So you went through a year of all of this, and then what did you do, because probably the Giants nor anyone else were going to hire you. **Rob Long ** 22:17 So I went through chemo, I actually, I worked out on my pro day, I probably shouldn't know. But I did. So I got to work out for a few of the NFL teams there. And, you know, over the next couple of years, I actually worked out for a handful of NFL teams. But once I kind of missed the draft, it becomes a very difficult league to break into there's jobs in the world, and every single one of them was filled the year before. So it's not only about being good enough, it's also about the opportunity that is presented. And so after about two years of of really trying to to make it work, I went back to school at Syracuse, I got my master's degree. And so I was trying to just keep things moving forward while still trying to fulfill this dream. And I went to a prospect camp in Arizona. And there was this sense of peace that I had, after going to that prospect camp that I had worked. For the last 24 months, I'd battled through 12 months of chemotherapy, I'd gone to the gym, I'd worked out, I'd done everything that I could do. And I pretty much went to that prospect camp and I said, I don't really care how this goes, go, I think I'm done. I think I'm done trying to play football. And I realized that I had you know, I was fortunate to be in a place that I didn't feel like I needed football to be successful. I felt like that I could go and do something else and and find a way to, to live my life that, you know, helped me be happy. And I didn't need football to do that. And I think that was a big turning point in my life that you know, I just had to walk away from from it on my terms. And I was super proud of myself for being able to get to that point. And I think that's something that you really allowed me to just close the book on that chapter of my life and be able to focus on the new hand of cards that I had been dealt. **Michael Hingson ** 24:31 You know, what's interesting, is that you clearly, were very committed to wanting to play football and it was what was driving you. But you were also able to take that leap and recognize, okay, things have changed. I know a lot of people don't seem to be able to do that when something else comes along. Why do you think that you were able to to actually go in a different direction and be comfortable about it because football had been said part of your life. **Rob Long ** 25:03 I think there was a lot that went into it, I think. I think I went through many, many mental health kind of struggles throughout the time since my diagnosis. And I think one of those, you know, there was this sense of anger that I had about my situation, that I felt that I kind of had been robbed of my dream. And I don't think I was able to process that in the most healthy of ways. And so, I got to a point for a while where I didn't really enjoy football, I didn't, I wouldn't watch it, I wouldn't, you know, be happy about going into practice, I would still do it. But I wasn't, I wasn't having fun, like, I lost that. Let fun. That was kind of what made football so amazing in the first place. And I think being able to kind of take a step back and just say, hey, like, you're, you're in a position that most kids dream about, you have the opportunity to play you played at Syracuse, you have the opportunity to try out in the NFL like, this is this is awesome like this, you should be happy for what you've done and where you've gotten to. And I think there was there's pieces of that where I was like, I want to be able to enjoy your my life and the things that come along with it. Knowing that I have absolutely no idea how much time I have left on this earth. You know, I just kind of felt like, I don't need to be seeking some other kind of form of validation of trying to figure out, you know, really where you're where my self worth was. And I wanted to be kind of in control of that, and to be able to move that forward. And I kind of realized that football was not going to be the path for me to be able to do that. **Michael Hingson ** 27:10 Well, what was your major when you were going through undergraduate? **Rob Long ** 27:16 So my undergrad was marketing and supply chain management. And then my master's was in New Media Management from the Newhouse School of Communications. So essentially, you know, a management degree from a communications school. **Michael Hingson ** 27:33 So a little different than undergraduate work, but still all about being in the management world, and you obviously made the leap and you, you then decided to do it. So how long ago did you get your Masters **Rob Long ** 27:48 2015 I, so about eight years, I finished my master's degree. And I got a job, I worked a couple jobs. And, you know, it was just doing sales at one point, and it just wasn't really feeling incredibly fulfilling. You know, it was work, it was okay. But I still having your left football and kind of that part of my life. It still hadn't, I didn't quite landed on where I was supposed to be. I had been working with opposing athletes as a kind of in a volunteer capacity. In 2012, my teammates at Syracuse started the Syracuse chapter of uplifting athletes in my honor. And it was, it was incredible. They got this, this thing started at Syracuse that had already existed, but started the Syracuse chapter, after my diagnosis. And I remained very involved with that. And it was something that I would talk to the team about, you know, each year and we would go and fundraise in the community and bring awareness to the rare disease community. And, for me, these little like, these little opportunities to kind of get a taste of of what this organization did, I was so drawn to it. And it's ultimately what led me to reach out to the founder of uplifting athletes in 2016. And I said, Hey, is there any chance that I could join this organization full time, and he was, you know, very receptive to having me on board. And so the timing worked out is such that, you know, our founder, had kind of built this organization for about seven years that he had really kind of built this grassroots movement to align sports with the rare disease community and I think it was just such a cool concept and I really loved that and I had experienced, you know, what benefits had been brought to me, you know, as an athlete. And so I think from that standpoint, it was something that I was like this this is it like this is this is something that I can I can do and I can be in Korea. really passionate about. So Scott brought me on up with the athletes in 2016. And he had started a for profit venture just about a year later. And so the timing worked out is such that I got to work it up with the athletes starting 2016. And then two years later in 2018, was promoted to the executive director role. And that is where it's just been an amazing opportunity for me to take my lived experiences, you know, as an athlete, as someone who was diagnosed with a rare disease, and take this awesome concept of an organization and kind of helped build it to what I believe it can become. **Michael Hingson ** 30:50 Well, you clearly found your niche, and you were open to looking, which is really probably at least half the battle anyway. But you, you did it, and you wanted to find something where you thought you could fit in, and it sounds like you have but tell us a little bit about what uplifting athletes is all about. **Rob Long ** 31:10 So one thing athletes, our mission is to build ours to harness the power of sport to build a community that invests in the lives of people impacted by Rare diseases. So what does this all mean is that we have the ability to take the platform that sports provides, and bring more awareness, attention and funding to the rare disease community. It's something that has been really incredible to be able to see the evolution of the organization, we kind of live at a cross section of, of sports and rare diseases. And so one of the things that was really fundamental to who we are at uplifting athletes when, when my colleague Brett and I took over leadership of the the organization was that you'll really want to focus on research. And so we knew that we needed to kind of develop a program that we really owned as an organization, we could get some sponsors for and we could celebrate, you know, the people doing amazing work in our community. And so, in 2018, we launched this this kind of crazy program at the time called the Young Investigator draft. It was modeled after the NFL Draft, but instead of drafting the top athletes in the country, we were drafting and funding the top researchers in the rare disease community. **Michael Hingson ** 32:35 So to deal with definitions, what are we classifying as a rare disease. **Rob Long ** 32:42 So a rare disease, there's over 10,000 Rare Diseases, rare disease in the United States is a condition that impacts less than 200,000 Americans in a given year. So of the 10,000 Rare Diseases, 95% of them do not have an FDA approved treatment. So we have over 30 million people in the United States living with a rare disease 27, over 27 million of them go to the doctors and do not have access to an FDA approved treatment. I realized pretty early on that I was one of the lucky few that had access to an FDA approved treatment. And that's why I'm sitting here having this conversation with you. And so really what our hope is through the Young Investigator draft is to invest in to fund and support the next generation of researchers. So that we can start to establish the pipeline of research that is required to bring a therapy to market. And so that's where the young investigator draft is born. We launched the program and 2018 and got to be honest, I didn't really know what I was doing at the time, but we seem to have figured it out along the way. And we've been able to partner with 33 different patient advocacy organizations in the rare disease space, and to fund 44 researchers and over $820,000 in research grants in the last four and a half years. **Michael Hingson ** 34:04 So how does sports get involved in all that? **Rob Long ** 34:08 So we kind of use the the concept, the excitement of sports to build up the draft specifically. So it's held at the eagle Stadium in Philadelphia. Everybody comes in, it's a draft environment. We have athletes that are making the picks. So we have our college student athletes that we work with, from our colleges and chapters across the country. They come and they're part of the event. And they get to call up the researchers who are going to be presented their research grants and so each researcher gets a jersey with their name on the back, just as if they were an athlete, but you importantly they get a research grant that allows them to move their research forward. **Michael Hingson ** 34:55 What are the sizes of some of the grants **Rob Long ** 34:59 so in Initially, we had our first year, we funded six researchers in $10,000. In grants. This past year, we funded 10, researchers and $20,000 $20,000 grants over $200,000 and research grants this year, and we're going to be doing at least that again in 2024. And that'll take us over a million dollars in research funded through our first six young investigator draft. So we've we've certainly made some headway. And we're really excited to see the progress that has been made with these research trends that we've been able to fund, have you been **Michael Hingson ** 35:35 able to reach out to people like any of the owners of sports teams, since there's usually some money there and talk with them about helping to fund some of the stuff? **Rob Long ** 35:47 Yeah, so it's part of kind of where we're at as an organization is trying to get more partners and supporters on board, we have a lot of the teams in the NFL specifically that we work with, we have a handful of Major League Baseball teams that we work with. And it's kind of one of the ways that we've been able to kind of take the next step as an organization. So we've talked about the research grant program, and we had kind of had the ability to reflect last year on, we've built kind of the first step in what we want to do as an organization invest in the next generation of research. Simultaneously, we had built this unbelievable network of athletes and professional sport teams that we were connected with. And so really in an effort to to leverage those relationships, we launched a new program late last fall, or I guess I should say, revitalized a program late last fall caught up with the experiences. And really what this does is provides people impacted by a rare diagnosis, the opportunity to connect with an athlete or a team, kind of similar to you know, make a wish type of situation, but being able to bring the entire family, the care partners, parents, siblings, and then we always try to bring, you know more than one family to our uplifting experiences events. Because as I said, there's a part of our mission is really to build that community. And so that's how we've been really able to leverage these sports partnerships and relationships is, is getting them to open their doors and roll at the red carpet for these families that otherwise would not have the opportunity to go to a baseball game or to go attend spring training in Florida or Arizona or go see behind the scenes of the Steelers stadium or in Kansas City at Arrowhead Stadium. And so we're providing these opportunities to not only get kind of a behind the scenes tour of, of these really unique venues, but also to go to the games, experience them and spend that time together. So **Michael Hingson ** 37:55 it's clearly not just dealing with the fundraising and dealing with the athletes, it's also dealing with the people who have rare diseases and trying to help motivate them to have some of the same successes that you've had. It sounds like, **Rob Long ** 38:11 correct, it's, it's really been about just providing opportunities for families to just feel included. And, you know, there's so much that you don't appreciate with what these families have to deal with, or that I didn't appreciate for what these families didn't have that have to deal with. It's, it's not just getting tickets and going to a game is, you know, what supplies do we need to bring with us? Where do we park? What entrance? Can we go through? How do we get to our seats, our seats together, as you know, their Ada, seating and all these other things that we as an organization, we take care of when we put together these events. Our goal is to make sure that the families that we work with have a truly positive experience. And I think, you know, big picture when we were talking about you know, how we build out this program and how it fits into what we do as an organization. It's really that, you know, we started and have continued and maintained the Young Investigator draft the research funding and even began to expand that a bit. And so we were doing this investment in the future we had, we're funding the next generation of researchers knowing that it's going to take those researchers a decade, two decades, three decades for them to take what they're doing today and for a treatment to be delivered. So what are we doing for the here and now what are we doing for the families that are going through this and this is what we want it up with experiences to be is an opportunity for us to engage with this community, the incredible incredible people that we have the honor to work with and to help facilitate these opportunities for you They're, they're unbelievably appreciative. And I think, you know, I think back to, you know, my time, when I was sick, you know, one of the best days of my life was being able to get back and just see my teammates and be around them. You know, and we weren't doing anything we, you know, we weren't even at practice, it was just like being there in the locker room with them together. And I think allowing these families the opportunity to go and do something that is so. So engaging and so fulfilling. You know, I think it really kind of fills them up, it provides them that hope. And shows them that there's, there's people out there that are working to to make their lives better. And I really believe that that's what the athletes that we work with are doing, the researchers that we work with are doing. And I know the staff that we have here and uplifting athletes is incredibly dedicated. And you're just driven by the mission that we have as an organization. **Michael Hingson ** 40:56 What exactly is the health equity initiative. **Rob Long ** 40:58 So for us, health equity has become something that we believe regardless, if you're in the rare disease community, we still want you to have the opportunity to have access to researchers and individuals that look like you. I think we we've come to learn how important diversity is in every facet of our life and medical research and medical care is no different. There have been studies out there that people adhere to treatment protocols. Better when they see a a doctor that looks like them. Research done in a more diverse lab can is as law has less biases implicated in it than traditional research. And so for us as an organization, we really wanted to not just have one thing that we did that is about health equity, it's really woven into the fabric of our organization. And so through the Young Investigator draft, you know, we ensure that we have one at least one researcher from an underrepresented background as defined by the NIH, included in every draft class, and that's been implemented over the last three years. For our research or travel program, we provide and reserve a portion of those stipends. For researchers from underrepresented backgrounds, there's so much that we're trying to kind of build out, especially when we're trying to engage with the next generation of researchers provide them the opportunities to pursue research in the rare disease community, through Young Investigator draft and just regardless of where you come from, or what you look like, we want you to feel welcomed and know that there's opportunities in the rare disease community. And so a big piece of what we're trying to do is meet researchers where they are doing speaking engagements all across the country. at colleges and universities that graduate, the highest percentage of researchers from underrepresented backgrounds are going to HBCUs and HSI guys that were able to connect and meet with these researchers where they are because ultimately, the rare disease community is, is as diverse as the general population. We have people from all walks of life, socio economic statuses, races, genders, and I think the community around them should should reflect that. And I think that's just something about, you know, who we want to be and and I believe in leading by example. And so we try to put this stuff these policies in place and and follow them and, and know that over time, you know, the good will come out of it. **Michael Hingson ** 43:52 Not that I have a question that comes up in my brain is, clearly you are an advocate and clearly uplifting athletes is advocating and a lot of different ways. Have you tried to do anything in the world of Washington to advocate and deal with legislation for more funding? Or is for creating more awareness for rare diseases and so on? **Rob Long ** 44:18 Yeah, so there are some great organizations that currently exist in the rare disease space that do a lot of policy work in Washington. So for us, we're trying to fill our, our niche, our kind of space in this, I believe, and part of my bigger vision for the organization of uplifting athletes is to get to a point where we can play a role both in policy at the state and national level. And so I kind of view your what we're doing as an organization as kind of baby steps kind of one step at a time and building that solid foundation. And it first started with kind of getting our own house in order or infrastructure in order and then you establishing the draft. And then once we've established the draft, we built some relationships. Now we can establish and build out up with experiences. And once that's been established, you know, what is next was the next opportunity for us. And I believe that as we grow, we have a growing number of colleges and universities that we work with, we have a growing number of professional sports teams that we work with, we're starting to have this reach that touches most of the continental United States. And I think that's a powerful mechanism by which we can leverage the relationships and the education that we've been able to provide to then take that next step into state and federal level advocacy. And I think, you know, there's, like I said, there's so many great organizations, like the everylife Foundation, and the National Organization for Rare disorder, rare disorders that do a lot currently on policy. And I think it's being able to amplify what what is already being done was already being said, opportunities to advocate for things like more funding for the NIH, newborn screening and genetic test, access to genetic testing, these are the things that really help us understand and and inform our decisions as we move forward as a community. And so those are the things that we're really want to get to. But I kind of have these two things that I believe have guided us to this point. And I always ask myself these these two questions. Before we really do anything, whether it's a new initiative or your whatever program. The first is, can we put everybody in a position to be successful? It is incredibly important to me that regardless of who you are, whether you're an employee, whether you're a family, part of our program, whether you're an athlete, whether you're a donor, can we fulfill our and of what we're asking? And if we can do that. Good. And then the second piece is, is everybody having an are we putting people in a position to have a quality experience with our organization, and as you're the leader of this organization, I believe it is my top my my responsibility to ensure that that is true for employees. It's true for the athletes, it's true for the families. And it's true for the donors and sponsors that support us. And those two questions are the things that can sometimes lead us to be more measured and methodical, and what we do. And there's a lot of potential for what we can do as an organization. But I add every step along the way, I want to ensure that people are having a quality experience, and that we're doing all that we can to hold up our end and ensure that we're putting people in a position to be successful. And that sometimes means that we have to sit on an idea or a plan until we're ready and able to execute it. And I think that's where you are, our growth has been a little bit measured and methodical, but really about focusing on quality and knowing that the community that we serve, often they have challenges when they go to the store, they have challenges when they go to school, they have challenges when they go to work. If they're going to interact with our organization, I do not want it to be a challenge. And so that's why we do what we do and kind of how we do it. And, you know, I've I've received a lot of feedback and criticism of why don't you do this? And why don't you do that? And why why is why are you doing this yet? And it's, it's understood, and I get it. And, you know, I just want to make sure that we're doing things the right way and building that strong foundation so that when whenever we take that next step, we're able to rely on everything that has come before it to make sure that we're successful. Yeah, **Michael Hingson ** 49:24 I hear you. And I know, I've been involved in advocacy for a long time. I'm a member of the largest consumer organization of blind people in the United States, the National Federation of the Blind, and back in the mid 70s. I think 1974 Maybe it was 73. But I think it was 74. The the organization started encouraging people to come at a particular time to Washington and started creating programs to advocate for particular legislation. And one of the things we learned early on is you know, You don't want to be a lobbyist, you don't want to hire a lobbyist. It's all about education, more than anything else, which is what I hear you doing. But it is a major effort to make it happen. On the other hand, there have been a lot, a lot of successes dealing with issues regarding blind people. And there's still some going on, and that have been going on now for a number of years, it's definitely more of a challenge to get some things through Congress these days, just because of the way things are. But still, it's it's possible, but but it has to be the right thing at the right time. So I hear exactly what you're saying, and you're really being very methodical about it, maybe starting at the state level, would be easier, because then you don't have to have such a huge process and undertaking to get something done. But those, again, are things that you clearly I think in listening to you study very well, and decide what to do at what time to make it the most effective thing it can be, which is, which is really good. **Rob Long ** 51:03 Thank you. Yeah, I, I, I'm really excited about the overall direction of the organization. And, you know, I haven't been doing it this long. But I believe we're just kind of scratching the surface of what we'll be able to accomplish in the future. And I believe that if we continue down this path, we continue to ensure that we're taking care of of the small things, we're taking care of ensuring that, you know, people have that quality experience that our employees are being given the tools and resources that they need to do their jobs. Well. You know, I believe that that will, we'll get where we're going in time. And it's just a matter of continuing to to make those right decisions and go down the right path and move things forward. **Michael Hingson ** 52:01 What do you find that athletes successful athletes today are getting out of associating with uplifting athletes and rare diseases. **Rob Long ** 52:13 We have the absolute privilege of working with some of the best people on this earth who also happen to be incredible athletes. I think thinking about the the specially the collegiate athletes that we work with, they have so much going on kind of in their lives, they're they're playing a high level of sport. They're at a high level academic institution. There's the social life that happens at college, and yet we have these these student athletes, and that, you know, that go on to sometimes be professional athletes that have the wherewithal at that age to say, how can I use the platform and the presence in the audience that I have, and make this world better. And for me, all the word trying to do is give them the tools that they need, understanding their limitations, your time limitations, their you know, financial limitations, what is it that you need from us in order to kind of help make this, this cause something that you're going to advocate for, and we have an awesome team here at uplifting athletes, that does a great job with that. And I think from the athletes, I think a lot of them, most of them do this out of the kindness of their heart, they want to give back they see that they can make the world a better place. But at the end of the day, I think what they get out of it is, is tremendous, because they might be somebody who doesn't get to play in the NFL or doesn't get to play professional soccer or whatever the sport is that we're working with. And what they can do is sit down in a job interview and say, Hey, I played football at Penn State. I graduated with a three six GPA. And I raised $50,000 for the rare disease community while I was in college, and that person is somebody that I want to hire and a lot of companies want to hire. And I think it's that that emotional intelligence that it shows and, you know, some of the athletes we work with have a connection to the community and some don't. And I think it's an incredibly inspirational to me to see how they all come about it from their own ways. You know, for me, I've experienced this right. I've been through a rare diagnosis. My family has been through through several and I get it and we have so many student athletes that we work with that they just want to help. They want to find a way to give back and I think that's just shows me there's there's a lot of good people in this world and the humanity and the humility that they have is, is exceptional. **Michael Hingson ** 55:15 Have you had any success at dealing with professional athletes after college? **Rob Long ** 55:19 We have. We've had a few that we've worked with that have been absolutely incredible. Two, two that I'll share with you is one. One is somebody who has literally came through our program. He was a leader of our Illinois chapter of uplifting athletes, and played on the offensive line at the University of Illinois had a great career there, ended up being drafted by the Kansas City Chiefs and won a Super Bowl his first year. His name is Nikki, Nick allegretti. And Nikki has been somebody that has just been incredibly loyal to us as an organization. He has done a tremendous amount in the Kansas City community for the families there that have been impacted by a rare diagnosis. He's hosted families at private tours of Arrowhead Stadium. He's come to Kansas City Royals games with us where we've been hosting families and doing meet and greets. He's hold holds camps at his high school. That benefit of both being athletes and for him to kind of come through this program as as a young college student, raise money at the college level, then use his platform as an NFL player to welcome in the Rosie's community has been fantastic. And then probably about three years ago, we were connected with a major league baseball player named Michael a tower. Michael, at the time, when we connected with him was a centerfielder for the Kansas City Royals. And we didn't know Michael's kind of whole story. But Michael was the sibling of somebody who lost their life to a rare diagnosis. Michael's sister died at the age of 21, from a very rare disease. And, you know, he came across our organization and just kind of loved the ease by which he could find a way to support and doing what he was already doing. And so Michael launched a hits campaign and raise money for every hit that he had during the MLB season. And this year, he is doing a home runs for rare diseases campaign and raising and donated himself $75,000 and getting the community to raise money for every home run that he hits this season. And so Michael's been centerfielder. Now with the Minnesota Twins, this is his second year with them. And it's been August, his first year with me he was traded last year from Kansas City, but he's been a fantastic ambassador and advocate. And just being able to use this platform. Every time he hits a homerun the twins talk about it, they do an in stadium announcement they do posts on social media. And I think it's it's that platform of sports where we're able to reach people that are in the rare disease community and be able to educate them and make them aware about the things that are happening, which is really special. **Michael Hingson ** 58:19 Yeah. No, no doubt about that. What? What kind of results can you point to that uplifting athletes has really brought through the years. **Rob Long ** 58:32 So I think for us the the the challenge with funding, the research that we fund is that it's very early stage. The amazing thing is that we have already had three researchers receive supplemental funding from the NIH. So this means that they've been taking those seed grants that we've provided, and being able to turn that into a larger sum of money to continue that research to move that research forward. So that for one is something that's really exciting. We've had over 800 people come through our equity experiences program since that was launched. Another thing that's just been incredible and providing hope and opportunity for families that that would not have them. And that's something that we're going to continue to do and continue to grow and invest. The one other story that I'll share with you on the research side, talking about impact. This year, I was preparing for our young investigator draft. And I previously mentioned that the chemotherapy that I took was the first ever chemotherapy approved to penetrate the blood brain barrier. It is still today the first line treatment for somebody diagnosed with a glioblastoma. I got curious about where that that medicine came from and who was essentially the inventor who was responsible for developing this therapy. And what I learned was that there was a gentleman named Dr. Mouth Um, Stevens and Dr. Malcolm Stevens. I looked him up, he is still alive. He's 85 years old. He's still doing research at the University of Nottingham in England. And so I reached out to him, I said, Dr. Stevens, it's a pleasure to meet you. My name is Rob, this is my story. This is the research that we fund and essentially, just wanted to thank you for for your work and, you know, developing the chemotherapy that saved my life. And about 10 days went by and I didn't hear anything and kind of figured that maybe email communication wasn't the best thing for somebody who is 85 years old, but I did eventually get an email back and Dr. Stevens wrote me, wrote me back and he said, Rob, it's so nice to hear from you. You know, I love the program that you've been, you've been running and I want to share with you a little story about how I developed Temodar, which is the chemotherapy and he said, back in the early, late 1970s, early 1980, he was trying to conduct research in in Birmingham. And at the time, in Birmingham, there was kind of like, general chaos, there was over 20% employment, there was strikes, there was riots, there was just kind of unrest in the streets. But all the while there was this, this Dr. Malcolm Stevens who was trying to do research, and he received a small seed grant from a nonprofit in England. And with that seed grant, he hired a research assistant. And him and his research assistant, whose name was also Rob first synthesized temozolomide in April of 1980. It took 27 years for temozolomide or Temodar to be FDA approved, but it was FDA approved in 2007. And 36 months later, I was diagnosed. And so it is that very research that was invested in in the 1980s. That is the reason that I'm here today. And so we've now funded 44 different researchers through our program, and my hope is that decades from now, each of them will have the opportunity to meet people that that they've impacted their lives with the work that they've done. **Michael Hingson ** 1:02:22 Now, as for you, have you played any more football at all? **Rob Long ** 1:02:27 No, I **Michael Hingson ** 1:02:30 was not going to do that. **Rob Long ** 1:02:32 I was I was done with that. I've moved on to other activities. I played hockey my whole life. But have recently well, for a while. I really love playing golf. So that **Michael Hingson ** 1:02:48 was gonna bring that up and ask him. **Rob Long ** 1:02:51 I told my wife, I needed some competitive outlet. So I've been doing golf, which I absolutely love. So I have not lost the competitive side of myself just trying to find different outlets for it. And **Michael Hingson ** 1:03:05 yeah, you just mentioned So you've now gotten yourself married, how long you've been married? **Rob Long ** 1:03:11 It is four years now. Well, not quite four and a half years. We my wife and I got married in May of 2019. And I aiming incredibly lucky, I often believe that I am the luckiest person in the world. You know, not only for what I've been through, but for the people that I have in my life and my wife is absolutely at the top of that list. **Michael Hingson ** 1:03:35 That is cool. And then you have two dogs and you're going to train them to go chase golf balls or what I do. **Rob Long ** 1:03:44 I don't know that training, training them to get golf balls, I might be a lost cause I just need to work on them not ruining the house first. There. Your first dog is a an Irish doodle. So he's an Irish setter. A standard poodle he was a COVID dog that we got at the beginning of the pandemic because my wife insisted that we had nothing else to do so my lava dog might as well have a dog. And then little over a year ago, we my wife was scouring the SPCA website and came across a rescue dog that was also an Irish doodle. And so we got our second dog his name's rocket and he's got half the size of Winston but has has firmly cemented himself as the alpha dog in the family. And so the two of them get along great and yeah, they're there. They're awesome. Yeah, **Michael Hingson ** 1:04:47 having animals is so much fun. We have a well I have my wife passed away last year we were married for two years and she she finally just the body wasn't keeping up with the spirit but I still have our are a cat that we rescued eight and a half years ago. And then also I have a guide dog Alamos. So it's me and the two critters and they keep me in line. And as I tell people, if I misbehave I'm sure I'm going to hear about it from Karen, somewhere along the line. Works out, **Rob Long ** 1:05:16 I'm sorry for your loss. But I'm glad that you have some unbelievable memories to hold on to. And the two creditors there to keep the company **Michael Hingson ** 1:05:27 40 years of marriages and memories is always a good thing. So I can't complain a bit. No regrets at all. But I'm really glad to hear your story. And I'm glad we had the chance to do this. I really appreciate your time. If people want to reach out to you and learn more about uplifting athletes and so on, how do they do that. **Rob Long ** 1:05:46 So they can find us at upliftingathletes.org. And across most social media platforms just by searching up within athletes. Personally, if you want to reach out to me, my social handles are almost all at rob R O B long, four, seven. So whether that's on Instagram or Twitter, or Gmail, wherever you need to get to me, you can and it'd be a pleasure to connect. But yeah, thank you so much for having me. I had the opportunity to listen to some of your previous shows and your your story is nothing short of amazing. And so I appreciate you taking your everything you've been through and turning it into a positive and, and talking to people like myself. So thank you for all that you. **Michael Hingson ** 1:06:41 If any thing comes up any way I can help, don't hesitate to reach out, you know how to get a hold of me and would love to be supportive in any way that I can. Awesome. Thank **Rob Long ** 1:06:52 you so much, Mike. Well, this **Michael Hingson ** 1:06:53 has been fun. And I hope all of you have enjoyed this and that you've learned some things please reach out to Rob, I'm sure that he would be glad to talk with you. Of course, I want to hear what you have to say. So I would really appreciate it. If you could reach out to me, let me know your thoughts, your comments or observations. You can reach me at Michaelhi at accessiBe A C C E S S I B E.com. Or go to www dot Michael hingson H i n g s o n.com/podcast. And wherever you're listening, please give us a five star rating. And I certainly asked you to please do all you can to support uplisting athletes. We all really appreciate it and value what Rob and the people are doing and we want to all help any way we can. So one last time. Rob, thank you very much. This has been a real joy to have you on. **Rob Long ** 1:07:46 Thanks so much for having me. **Michael Hingson ** 1:07:51 You have been listening to the Unstoppable Mindset podcast. Thanks for dropping by. I hope that you'll join us again next week, and in future weeks for upcoming episodes. To subscribe to our podcast and to learn about upcoming episodes, please visit www dot Michael hingson.com slash podcast. Michael Hingson is spelled m i c h a e l h i n g s o n. While you're on the site., please use the form there to recommend people who we ought to interview in upcoming editions of the show. And also, we ask you and urge you to invite your friends to join us in the future. If you know of any one or any organization needing a speaker for an event, please email me at speaker at Michael hingson.com. I appreciate it very much. To learn more about the concept of blinded by fear, please visit www dot Michael hingson.com forward slash blinded by fear and while you're there, feel free to pick up a copy of my free eBook entitled blinded by fear. The unstoppable mindset podcast is provided by access cast an initiative of accessiBe and is sponsored by accessiBe. Please visit www.accessibe.com. AccessiBe is spelled a c c e s s i b e. There you can learn all about how you can make your website inclusive for all persons with disabilities and how you can help make the internet fully inclusive by 2025. Thanks again
In this episode of the Smarter Not Harder Podcast, our guest Dr. Susan Rossell joins our host Jodi Duval to give one-cent solutions to life's $64,000 questions that include: How have the media and popular culture shaped our perceptions of what the ideal body should look like and how these influences can lead to serious psychological and social implications? How does body dysmorphic disorder (BDD) affect people emotionally and socially making it difficult for them to recognize and respond to the emotions of others? What are the current and upcoming treatment options available for body image disorders, including psychotherapy, antidepressants, oxytocin, and brain training? Dr. Susan Rossell is a cognitive neuropsychologist and Professorial Research Fellow at Swinburne's Centre for Mental Health. She also holds adjunct positions at Monash Alfred Psychiatry Research Centre and at St Vincent's Health. Professor Rossell's research focuses on understanding the cognitive and neurobiological processes involved in psychosis and related disorders. She has published extensively and received both the International and European award for Young Investigator in Schizophrenia Research. What we discuss: (0:02:00) - Body Image (0:04:30) - Toxic Body Positivity (0:07:10) - Body Dysmorphia Through a Biological and Psychological Perspective (0:13:21) - Body Dysmorphia's Impact on Emotions (0:19:42) - Gender Differences in Body Image Disorders (0:22:10) - Body Image versus Vanity (0:26:27) - The Rise of Dsitress in Body Image (0:29:55) - Fear of Aging (0:34:15) - The Impact of Social Media Filters (0:40:57) - Body Image Treatment Options (0:48:06) - Body Image Survey and Getting Help (0:52:36) - Knowledge, Psilocybin, and Body Image Find more from Smarter Not Harder: Website: https://troscriptions.com/blogs/podcast | https://homehope.org Instagram: @troscriptions | @homehopeorg Find out more from Dr. Susan Rossell Twitter: @RossellSusan Get 10% Off Your Purchase of the Metabolomics Module by using PODCAST10 at https://www.homehope.org Get 10% Off your Troscriptions purchase by using POD10 at https://www.troscriptions.com Get daily content from the hosts of Smarter Not Harder by following @troscriptions on Instagram.
Dr. Vinh Chung continues our conversation on inspirational leadership, the barriers that physicians often face in leading well, and acts of service. Dr. Vinh Chung, MD is a dermatologist and Mohs surgeon who specializes in the diagnosis and treatment of skin cancer. He obtained a BA in biology at Harvard University and earned his medical degree from Harvard Medical School. He was a Fulbright Scholar and also earned a Master's of Theology from the University of Edinburgh. He received the Theodore Tromovitch Award from the American College of Mohs Surgery as well as the Young Investigator's Award from the American Society for Dermatologic Surgery. He has written a memoir titled, Where the Wind Leads, and has a recent article in Practical Dermatology on moral injury and burnout. He lives in Colorado Springs with his wife and four children.
Dr. Vinh Chung introduces me to the concept of moral injury and how that leads to physician burnout. He also begins to talk about leadership that goes beyond power and authority to a place of trust and inspiration. Dr. Vinh Chung, MD is a dermatologist and Mohs surgeon who specializes in the diagnosis and treatment of skin cancer. He obtained a BA in biology at Harvard University and earned his medical degree from Harvard Medical School. He was a Fulbright Scholar and also earned a Master's of Theology from the University of Edinburgh. He received the Theodore Tromovitch Award from the American College of Mohs Surgery as well as the Young Investigator's Award from the American Society for Dermatologic Surgery. He has written a memoir titled, Where the Wind Leads, and has a recent article in Practical Dermatology on moral injury and burnout. He lives in Colorado Springs with his wife and four children.
Timeline:3:18 Women oxidize fat better than men. This purportedly “should” provide a performance advantage to women in ultra-endurance events. Yet men still win these events and hold the records (in the aggregate). What does Dr. Smith-Ryan say about this?7:48 Are there sex differences vis a vis skeletal muscle fiber type? Are women more fatigue-resistant10:17 Birth control – effects on performance and/or substrate utilization14:07 The only sample that matters is you!15:00 The menstrual cycle – the effects on various indices of female physiology; TDEE goes up by 300-400 kcals!21:00 High end female athletes often want to be amenorrheic – Dr. Smith-Ryan opines.24:46 What is muscle quality? Lift heavy shit.27:07 Many reps with light weights or lift heavy weights with fewer reps? Why Abbie finds this comparison annoying.30:30 HIIT vs steady-state aerobic training – the value of each. NOBODY does hit every day. Because if you say that, you are lying to yourself.35:04 Sex differences in the adaptive response to HIIT?38:22 Sex differences in pain perception? Is it real? Do women perceive less pain post-DOMS protocol?41:40 Protein needs in athletic women vs men? Abbie consumes enough protein
"Who Was That Masked Man?" The Lone Ranger is one of the iconic characters in American folklore. The Lone Ranger and Tonto are two of America's favorite western characters, and the theme and bridge music caused many thousands of kids to grow up to liking classical music, too. Listen to our radio station Old Time Radio https://link.radioking.com/otradio Listen to other Shows at My Classic Radio https://www.myclassicradio.net/ Remember that times have changed, and some shows might not reflect the standards of today's politically correct society. The shows do not necessarily reflect the views, standards, or beliefs of Entertainment Radio
"Who Was That Masked Man?" The Lone Ranger is one of the iconic characters in American folklore.The Lone Ranger and Tonto are two of America's favorite western characters, and the theme and bridge music caused many thousands of kids to grow up to liking classical music, too.Listen to our radio station Old Time Radio https://link.radioking.com/otradioListen to other Shows at My Classic Radio https://www.myclassicradio.net/Remember that times have changed, and some shows might not reflect the standards of today's politically correct society. The shows do not necessarily reflect the views, standards, or beliefs of Entertainment Radio
Part 2 of our conversation with Dr. Tim Hewitt. Dr. Tim Hewett has dedicated his life to the epidemic problem of Anterior Cruciate Ligament ruptures across all athletics. During his research, he has held appointments at Ohio State, The Mayo Clinic, and several other prestigious universities. Dr. Tim Hewett has received several prestigious awards, including the NCAA, Excellence in Research and O'Donoghue Awards from the American Orthopedic Society for Sports Medicine, Rose Excellence in Research Award from APTA, and a Young Investigator's Award from the American Heart Association, and received the Clint Thompson Award for best paper from the National Athletic Trainers Association. His work has been cited in over 1000 lay press journals, including The New York Times, Wall Street Journal, USA Today, Fox News, and CBS. If you treat athletes pre or post-ACL rupture, these next two episodes are for you! Show Notes Dr. Tim Hewett Part 1 --- Support this podcast: https://anchor.fm/gestalt-education/support
Dr. Tim Hewett has dedicated his life to the epidemic problem of Anterior Cruciate Ligament ruptures across all athletics. During his research, he has held appointments at Ohio State, The Mayo Clinic, and several other prestigious universities. Dr. Tim Hewett has received several prestigious awards, including the NCAA, Excellence in Research and O'Donoghue Awards from the American Orthopedic Society for Sports Medicine, Rose Excellence in Research Award from APTA, and a Young Investigator's Award from the American Heart Association, and received the Clint Thompson Award for best paper from the National Athletic Trainers Association. His work has been cited in over 1000 lay press journals, including The New York Times, Wall Street Journal, USA Today, Fox News, and CBS. If you treat athletes pre or post-ACL rupture, these next two episodes are for you! --- Support this podcast: https://anchor.fm/gestalt-education/support
In this episode of AAHKS Amplified, Digital Health and Social Media Committee vice chair William B. Kurtz, MD speaks with AAHKS 2022 James A. Rand Young Investigator's Award recipient, Vishal Hegde, MD. He is joined by fellow Digital Health and Social Media Committee member, Eli Kamara, MD. They discuss Dr. Hegde's award-winning paper “Increased Revision […] The post AAHKS 2022 James A. Rand Young Investigator's Award Recipient first appeared on AAHKS.
Dr. Charles Ryan, president and CEO of the Prostate Cancer Foundation (PCF), joins ASCO Daily News Editor-in-Chief Dr. Neeraj Agarwal, of the University of Utah Huntsman Cancer Institute, to assess impactful prostate cancer research from the PCF's recent conference and discuss Dr. Ryan's vision for the future, including increasing access to cutting-edge care. TRANSCRIPT Dr. Neeraj Agarwal: Welcome, to the ASCO Daily News Podcast. I'm Dr. Neeraj Agarwal, the editor-in-chief of the ASCO Daily News, and director of the Genitourinary Cancers Program at the University of Utah Huntsman Cancer Institute. Today, we'll be discussing compelling research that was featured at the recent Prostate Cancer Foundation Scientific Retreat, and I'm very pleased to welcome Dr. Charles Ryan, the president, and CEO of the Prostate Cancer Foundation. Our full disclosures are available on the transcript of this episode, and disclosures relating to all episodes of the ASCO Daily News Podcast are available on our transcripts at: asco.org/podcasts. Dr. Ryan, thank you for taking the time to be with us today. Dr. Charles Ryan: Dr. Agarwal, thank you. It's my pleasure to be with you. Dr. Neeraj Agarwal: So, Dr. Ryan, before I discuss the PCF meeting, I would like to ask you, what made you move to the PCF as the president and CEO when you had a flourishing career as a division chief of a large academic program, and as one of the top and internationally recognized investigators in prostate cancer? Dr. Charles Ryan: Well, thanks. That's a fair question, I guess. And it took me about three minutes to make the decision when I was offered the position, simply because the Prostate Cancer Foundation has been one of my intellectual homes for my entire career. I've been at the University of Wisconsin, Memorial Sloan Kettering Cancer Center, UCSF, and the University of Minnesota, and all those institutions were affected by the Prostate Cancer Foundation, or previously, CaP CURE. So, I was involved in their research during my time at all those institutions. In addition to my own personal legacy with the PCF, but more importantly, is the fact that it is an organization that funds the deepest scientific inquiry into prostate cancer and the ways that it can cause suffering and death for men with the disease and has made tremendous progress in identifying factors that lead to that lethality. It's also a community of scholars, a community of researchers, that is a platform really for collaboration. And it's also an organization with a world reach - we fund research in 28 countries around the world, and we fund research going from the scope of very basic research to correlative research, to quality of life, and health services research. Dr. Neeraj Agarwal: That is truly impressive and inspiring. So, what is the mission of the Prostate Cancer Foundation formally? Dr. Charles Ryan: Formally, it's pretty simple. The mission of the Prostate Cancer Foundation is to reduce the death and suffering from prostate cancer. Dr. Neeraj Agarwal: So, the 29th PCF Scientific Retreat was recently held on October 27 to October 29th in Carlsbad, California. What were the goals and objectives of this meeting? Dr. Charles Ryan: The meeting, we call it the retreat, it's an annual event and it always has several goals. One is, it's where we announce and hand out, if you will, our awardees of our various awards that we give. It's also a reporting-in process where those who have been using PCF funding are called to come and discuss their work. We also want it to be an open forum for individuals to come and interact - it's really a collaboration and an interaction vehicle as much as anything. So, when you come to our scientific retreat, we all stay at the same hotel, we all share meals together, nobody goes out for dinner. You don't leave the campus, essentially, of the hotel where we are. We have many, many round tables set out, it's designed to be interactive. We have a big room where people are giving their talks, but if you step outside of the room, there are likely to be many, many conversations happening, and those conversations range from collaborations being formed to people looking for jobs, to people getting advice and mentoring, and even people sharing, as I've done over the years, compelling and challenging patient stories around prostate cancer, and really engaging in what communities do - which is, share ideals, share a mission, and share a passion for what they do. Dr. Neeraj Agarwal: Very interesting. Very inspiring. Please tell us some of the highlights of the meeting. Dr. Charles Ryan: Sure. Well, there are many highlights. There are many things happening in prostate cancer research. Most notably, there are a number of papers and investigators that are looking at how prostate cancer evolves, and probably the most significant set of observations that have been made in the field in the last decade, have been understanding the diverse and numerous mechanisms that underlie the evolution of prostate cancer from a disease that responds to hormonal manipulation, to one that becomes resistant to hormonal manipulation. And so, a lot of the work that's happening now is identifying, for example, the evolution of neuroendocrine prostate cancer, or mixed types of prostate cancer, or this sort of evolution of it under constant therapy. And that is allowing the exposure of new targets that we can exploit for new therapy development, and that feeds into some of the grant-making process that's going on in the background. And so, you have a lot of individuals who are looking at this or that mechanism pathway related to disease resistance that they can exploit, and whether they can create small molecules to do that, or antibodies to do that, et cetera. At the same time, we have a strong component of discussion of how prostate cancer affects different populations. So, we had some really nice talks looking at healthcare disparities and different populations across the world, and how they're affected by prostate cancer, and how care delivery may be impacted in those groups of patients. And then you have topics ranging around survivorship and other factors that are looking at what is life like for a man with advanced prostate cancer, which is in many cases, you know, men who get prostate cancer, who have recurrent disease, who end up going on systemic therapy are frequently on the treatment for 5, 10, 15 years. And so, survivorship, and how they live their life, and what the complications are of that treatment, is tremendously important because it's such a daily experience for these men undergoing treatment. Dr. Neeraj Agarwal: So, how does the Prostate Cancer Foundation support and build the next generation of prostate cancer researchers? Dr. Charles Ryan: Right. So, the PCF supports the next generation in a very specific way, in addition to the informal way of bringing people together and inducing collaborations. We have a program called the Young Investigator Program. It started formally in 2008, but before that, there were one-off, if you will, Young Investigator Awards being given. So, our Young Investigator Awardees receive $75,000 per year to support their work, and we awarded 34 of those this year. The range is somewhere from 25 to 34 per year. We get over 100 applications for them every year. It's a straightforward application - they need to have a project that's going to be about three years in length, they need to be mentored, and they are best served by describing a mentorship plan for themselves and how that mentorship relationship will help them grow in their careers. Now, once you become a Young Investigator, it's not that we just write you a check and wish you well, we do that, but we also have annual check-ins. So, we try to visit the sites of our Young Investigators, see them in their home institution, and meet with their colleagues and their mentors. And that's one of the things I do, or Howard Soule does-- Howard Soule, is our chief scientific officer, one of those things we try to do. We also bring them to the scientific retreat that we just had last week, and we have them present their data. So, a vast number of the individuals who are presenting at the scientific retreat are in fact, Young Investigators, or they were Young Investigators when they started the projects that they are presenting. And then, the other thing we do is we have another retreat specifically for the Young Investigators, and that's called the Coffey-Holden Retreat, and that's named after Don Coffey, the late researcher from Johns Hopkins, who is really considered to be one of the grandfathers of prostate cancer research, and Stuart or Skip Holden, who is one of the founders of the Prostate Cancer Foundation, and a urologist at UCLA. So, that event that we do is designed for people to come to give highlights of the work that they're doing; it's designed to be incredibly interactive. In fact, we have 15 or so minutes of presentation, followed by sometimes 25 minutes of questions for each presenter. There's always a line of people who are waiting to ask questions, and it's designed to engage and have that dialogue with the Young Investigators, to make their science better, and to get it known. And so, the Young Investigator Program, it's about 30 individuals per year on average, and the average age is about 30. Many of these are postdoctoral PhDs, and many of them are fellows, or early-stage faculty, MDs. And I like to think that if somebody's going to work until the age of 70, we're stimulating, or launching a 40-year career with these Young Investigator awards. So, I like to think that if we give 25 out, times 40 years, that's 1,000 years of research that we're sort of stimulating with this Young Investigator program. And I bring that up for the reason that we're very proud of the fact that many of our Young Investigators may start out in prostate cancer, and their ideas, their science, takes them elsewhere. And that's what science does. And we, of course, are very, very focused on solving the problem of prostate cancer, and we want people to do that. But we also understand that by launching a scientist, by launching a scientific career, you may end up with people going off in different directions. And so, we have many examples of that. And in my talk this year, I actually highlighted a person who, let's say she won an investigator award when she was young, it was before the formal Young Investigator Award was named, and this was a person who is creating conjugates for the delivery of chemotherapy to prostate cancer cells. And this was Carolyn Bertozzi up at UC Berkeley, and she just won the Nobel Prize. She didn't win the Nobel Prize for research she did on prostate cancer, but at some point, at one point in her career, this was a direction she was going, and she got two grants from us in 1999 and 2000, that helped her work continue on and go the direction that it did. Dr. Neeraj Agarwal: Yeah. And congratulations. Dr. Charles Ryan: Sure. I'll take credit for that one. Dr. Neeraj Agarwal: Being the President and the CEO, you deserve the credit. Dr. Charles Ryan: Sure. That's my job. Dr. Neeraj Agarwal: So, we are coming to the end of the interview, but let me ask you this; the prostate cancer field is so constantly evolving. What is your vision for PCF going forward? Dr. Charles Ryan: Well, my vision for the organization is that we are going to continue on our mission to reduce the death and suffering from prostate cancer. But that's a fairly general statement, and one of the ways you can do that is you can research cancer at a molecular level, and you could try to develop new therapies - we're going to continue to do that. But there's also a real problem, especially, in the United States, and actually globally, with individuals with prostate cancer who are not receiving the cutting-edge care, not receiving the cutting-edge therapy. We have some data that in the United States, maybe upwards of 50% of men with metastatic hormone-sensitive prostate cancer are not getting the therapies that are supported by the latest findings from randomized phase III trials. And this may be for economic reasons, it may be communications or an education deficit with their treating clinicians, and there may be other factors as well. So, as we think about the vision of this, we need to be mindful of that, because if we only focus on studying the cancer molecularly, and we don't address what's happening on the other end, then we're not completing the story, and we're not completing the mission. And so, I've started calling Prostate Cancer Foundation the Global Public Square of Prostate Cancer, because I think of four sides of that square - funding research, as of what we just got done talking about, education and communication, is another one, and we do that in the same way that you are doing this today - through podcasts, and web content, and in-person meetings, as well as applied discovery, which is helping our researchers take their discoveries or their findings out into the clinic. Now, you might think, "Well, that's a small molecule, becoming a company going into a phase I clinical trial." Certainly, that's part of it, but it's also the epidemiologist who is making observations about diet and exercise, who is then empowered to do a clinical trial of exercise and diet intervention. It's also the health services researcher who is able to use their data to go talk to payers or talk to organizations about how care may be delivered differently. So, that's applied discovery. And then finally, supporting the patient is part of what we do. So, we also hold patient webinars every month, we've held patient summits at various points around the country where we bring patients together and talk to them about the latest research or about the factors we've discussed, such as survivorship, or quality of life after treatment, or treatment complications, and things like that. Dr. Neeraj Agarwal: That's wonderful. Thank you so much for sharing your insights. Any final remarks, Dr. Ryan? Dr. Charles Ryan: Dr. Agarwal, thank you so much. It's always a pleasure to speak to another Genitourinary Oncologist, of course, about the field, and the opportunity to talk about the Prostate Cancer Foundation and what we're doing, and the directions we are trying to grow. We've had a great collaboration with ASCO over the years, and I hope that that continues as well. I hope anybody who is interested would come and visit us at: pcf.org, and they can also check us out on: urotoday.com, where we have a lot of content that might be of interest to them. Dr. Neeraj Agarwal: Thank you, Dr. Ryan, for taking the time to be with us on the ASCO Daily News Podcast today. And thank you to our listeners for joining us today. If you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe, wherever you get your podcast. Thank you very much. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy, should not be construed as an ASCO endorsement. Follow today's Speakers: Dr. Neeraj Agarwal @neerajaimms Dr. Charles Ryan @charlesryanmd Want more related content? Listen to our podcast on therapeutic advances in prostate cancer and other GU cancers. Advances in Genitourinary Cancers at #ASCO22 Follow ASCO on social media: @ASCO on Twitter ASCO on Facebook ASCO on LinkedIn Disclosures: Dr. Neeraj Agarwal: Consulting or Advisory Role: Pfizer, Medivation/Astellas, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Pfizer, Merck, Novartis, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, Gilead Sciences Research Funding (Inst.): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck , Lilly, Nektar, ORIC Pharmaceuticals, crispr therapeutics, Arvinas Dr. Charles Ryan: Honoraria: Janssen Oncology, Bayer Consulting or Advisory Role: Bayer, Dendreon, AAA, Myovant Sciences, Roivant, Clovis Oncology
On this episode of Bone Talk, BHOF CEO Claire Gill talks to Dr. Rodrigo Valderrábano. His research focus is on metabolic bone disease and during his time as a research fellow at Stanford University, he was awarded the Endocrine Society's Outstanding Abstract award and the American Society for Bone and Mineral Research's Young Investigator award for his work studying the links between bone health and hematopoiesis in older men. He continues his research efforts with the ultimate goal of further delineating treatable risk factors for osteoporosis and devising non-pharmacologic treatment strategies for osteoporosis such as rehabilitation and exercise.
Dr. Stephen Moran, Ph.D., is Global Program Head, Neuroendocrine Tumors & Other Radiosensitive Cancers, for Advanced Accelerator Applications (AAA - https://www.adacap.com/), a Novartis company and also a member of the Oncology Development Unit Leadership Team at Novartis. Prior to joining AAA, Dr. Moran was Global Head of Novartis Strategy, where he played a key role in defining the company's strategy, prioritizing critical actions needed to deliver on the mission to discover new ways to extend and improve peoples' lives. He also led numerous strategic initiatives, including gene therapy (AveXis, now Novartis Gene Therapies), RNA therapeutics (The Medicines Company), precision medicine and digital strategies. Dr. Moran joined Novartis as Strategic Assistant to the CEO, a position he held for two years and prior to this, he was an associate principal at McKinsey & Company serving as a leader in the healthcare practice, where he focused on health system sustainability, research and development strategy, and the economic analysis of clinical interventions across disease pathways. Dr. Moran holds a Bachelor of Arts and a Master of Science in Biochemistry from the University of Cambridge in the United Kingdom, including an undergraduate exchange program at the Massachusetts Institute of Technology (MIT). He also received a Doctorate from the University of Oxford in Biophysics where he lectured on thermodynamics, quantum mechanics and electromagnetism as applied to biology. Dr. Moran has also been a guest lecturer in strategy at the University of St. Gallen International Executives MBA, masters and bachelor courses, and received the Young Investigator of the Year award in 2006 from Biochemical Journal.
Dr. Abbie Smith-Ryan joins us to talk about fitness, body composition, and metabolism, with a focus on women's health. We discuss practical ways to apply the latest research to support your health and fitness. Abbie Smith-Ryan, PhD is a professor of exercise physiology and sports nutrition at UNC Chapel Hill. She directs the Applied Physiology Lab and is a fellow of several professional organizations including the International Society of Sports Nutrition (ISSN), the American College of Sports Medicine (ACSM), and the National Strength & Conditioning Association (NSCA). Dr. Smith-Ryan has received numerous awards including Nutrition Researcher of the year and Young Investigator of the Year for the NCSA. Her research focuses on exercise and nutrition interventions to modify body composition, cardiovascular health, and metabolic function. She is extremely passionate about women's health and has recently been studying the menopause transition. In this episode, we discuss: Body composition: Why the number on the scale is not the best predictor of health; how body composition is affected by menopause and aging. Metabolism: What the term "metabolism really means, how it's measured, and how much we can, and cannot, control it. Muscle: Why women should prioritize muscle mass; why building and maintaining high quality muscle is so important, especially as we age. Fitness: Which types of exercise give you the most "bang for your buck" Connect with Dr. Smith-Ryan through her website, Twitter or Instagram: https://www.asmithryan.com/ https://twitter.com/asmithryan https://www.instagram.com/asmithryan/ Studies Metabolic effects of menopause: a cross-sectional characterization of body composition and exercise metabolism (2022) https://pubmed.ncbi.nlm.nih.gov/35231009/
16 February 2022 - The EMBO Young Investigator Programme (YIP) was created in 2002 to support researchers starting their first lab (to be eligible, “applicants must have been an independent group leader for at least one year and for less than four years”). The programme provides mentorship, training, and networking opportunities for both the PIs and their lab members. Applications for the YIP programme are currently open. The EMBO podcast spoke with a YIP alumnus, immunologist Matteo Iannacone, and a recently selected member of the programme, neuroscientist Katrin Franke.
Today I'm speaking with Dr. Nitesh Sood, an electrophysiologist who is board-certified in internal medicine and holds certifications in echocardiography, nuclear medicine, and cardiovascular disease. Dr. Sood is currently the Director of the Atrial Fibrillation Wellness Program at Southcoast Physicians Group in Dartmouth, Massachusetts.Dr. Sood was selected as “Star Fellow” “Fellow Elite in Training” 2012 by the American College of Cardiology (ACC) and also “Young Investigator of the year” 2012. Dr. Sood has a special interest in treating patients with atrial fibrillation, syncope, and implantation of pacemakers and implantable cardioverter-defibrillators.Sood was the first electrophysiologist to utilize pulse-field ablation and has now completed 33 procedures using PFA for atrial fibrillation, more than any other physician in the world at this point. Join us for a discussion on the use of pulse-field ablation, and its many advantages over cryo or radiofrequency ablation.Discussion points:Introduction and background – Dr. Nitesh SoodWhy PFA and how has cryo ablation progressed over timePFA is very young, has only existed for about 20 yearsApoptosis vs. necrosis in ablation proceduresWhat structures may be at risk when performing ablationAnimal studies have shown that PFA causes minimal damage in many at-risk areasPFA has potential for temporary nano-pores that can be useful for delivering medicine such as those used for cancer treatmentMRI data shows incredible cell recovery 3 mos. After PFA, vs. radiofrequency ablationThe length of time needed for PFA is much shorter than cryo or radio, thus minimizing risks of time under anesthesiaThe learning curve for PFA is around 4-5 casesOther uses and some minimal risks of PFAAfib is on the increase, partly due to more monitoring and tests being availableAfib can easily be monitored by patients themselves, with things like Fitbit and Apple watches, to help doctors treat them more effectivelyTake a look at our website ClubAfib.com to find out more and track your own Afib– give us your feedback!Resources:Dr. Nitesh Sood at Southcoast Physicians GroupDr. Nitesh Sood LinkedInClubAfib.com WebsiteDr. Kiankhooy LinkedInAll Things AFib WebsiteAll Things AFib TwitterAll Things AFib YouTube Channel
Lung cancer is a disease that affects people: family, friends, co-workers, neighbors. It's a disease that comes with in some stark figures about survival and research funding. But the numbers don't lie, and they also show the amazing strides being made against the disease: increasing survival rates, incredible strides in treatment options, and ever-growing ranks of researchers dedicating their professional careers to improving the odds for people living with lung cancer. Join us for this episode of Hope With Answers: Living With Lung Cancer, where we talk about hope, by the numbers. Guests: Kim Norris, Lung Cancer Foundation of America co-founder and president Dr. Jessica Donington, professor of surgery at the University of Chicago Pritzker School of Medicine Dr. Triparna Sen, an assistant attending at Memorial Sloan Kettering Cancer Center Kellie Smith, PhD, assistant professor of oncology at Johns Hopkins Medicine Show Notes | Transcript BY THE NUMBERS: 20 The quickening pace of research the last 20 years Twenty years ago, the lung cancer treatments available were surgery, chemotherapy, and radiation. Then came the discovery of treatable lung cancer biomarkers. The discovery that each lung cancer tumor is unique opened up a whole new world of discovery. After that, immunotherapy opened up even more ways to treat different types of lung cancer. And for many people, living with lung cancer it has become more like managing a chronic disease rather than the usually fatal diagnosis it was just a handful of years ago. “... the entire landscape has changed for people diagnosed with lung cancer. I even wonder if my husband, who died 20 years ago, would still be alive if he had been able to take advantage of all the research that's been happening in just the past five or ten years. We now know people living 8, 13, 15, and 19 years after diagnosis. And then we realized that these numbers are really powerful-- they're not just black and white numbers, they're people.“ - Kim Norris BY THE NUMBERS: Double Duty LCFA Young Investigator Research Grants do double duty in the field of lung cancer research. Funding from foundations like the Lung Cancer Foundation of America is essential in building a pool of investigators. It takes a long time and a lot of money to go from a great idea and a bright star with a great mind to an NIH-funded investigator. But as Dr. Triparna Sen points out, these grants also help to train young investigators. “Like with this funding, we get postdocs and trainees and technicians into the lab. So we are essentially training the next generation of cancer investigators who will go on to become in independent investigators themselves. So you're not only just providing resource to advanced research, but you're also providing resource to train the next generation of cancer investigators. And I think that has a much more long term impact the next clinical trial. So I think overall, uh, the funding that I got from LCFA has been absolutely critical in developing me as a researcher. So thank you so much.” BY THE NUMBERS: 17 LCFA has invested in 17 grants so far, and 10 of them have gone to women. Women in science face many challenges. When Dr. Donington got into lung cancer 15 years ago, it was a very male-dominated field in terms of the doctors who treated it and the researchers who performed the research. And I always believe that a group of physicians and researchers that matches their patients provides the best care. The Power Of The Patient Advocate Voice Women advocates are making a difference in lung cancer research as well. As Dr. Donington discusses, “Lung cancer for a long time has had a stigma issue as being seen as a male disease, with people who have smoked for 100 years. And it's just not, it's not that disease. And I think that our advocates which are very heavily female like a lot of cancer advocates are, have really done so much to change the face of lung cancer…. I think they do more to change lung cancer than even us as investigators.” Dr. Sen thinks that what the patient advocates do is they help bring system-wide issues to light that are required for clinical trial design for what is important for the actual patients who is the ultimate goal role for our researchers. And her goal is to work with patient advocates to make her scientific studies more relevant to the field, more timely, because she now understand by speaking to them the urgency of the situation, and so make it more timely. “And I think patient advocates play a very important role to help researchers learn like myself move discoveries towards clinical use, but do that in a more sort of not only timely fashion, but also help us design studies that are more relevant to clinical use.” - Dr. Triparna Sen In addition, patient advocates play an important role in bringing these disparities to light. Then these issues can be addressed by researchers and by clinicians and move them to incorporating equity in clinical trial. “I think so they play a very important role at multiple levels and LCFA has done an incredible job in connecting researchers to patient advocates.” - Dr. Triparna Sen The Pace of Research: Bench to Bedside “And I didn't think it was possible in my lifetime, but I suddenly think that, oh my gosh, we can double survival. We can get survival up to 25 and 30%. I feel like in a very short time, uh, with screening and the advancements in our current medications, it's just so possible. It's exciting.” - Dr. Jessica Donington The time it takes for research to go from bench to bedside is getting faster all time. That's the timeline: how long it takes for a discovery in the lab to make it to a patient who needs it. So, for example, when you're in a laboratory you hear about using mice and discoveries, but that's just in theory, then you have to bring it to the human and that takes time. “Bench to bedside has never been as fast as it is now in lung cancer. It is incredible. Things we never considered as little as five years ago are just commonplace now. It was very funny I was working with one of my colleagues and she said, "Oh, yeah, I don't treat one person the same way I did five years ago as a medical oncologist." And then I sat down and go, "Oh, you know what? I don't either." Like none of us do. So there's this whole synergy about the science too, as it advances in one area, it becomes easier to integrate it into others and it's really exciting.” - Dr. Jessica Donington Research breakthroughs discovered five, six years ago are already in clinical trials. So this bench to bedside medicine is a phenomenal thing to be a part of within the context of lung cancer. “As a PhD scientist, we very rarely see the fruits of our labor actually pan out in the clinic. I mean, it's very rare. But with lung cancer research, because it's moving at such a rapid pace, we are able to see these discoveries making their way into the clinic in an accelerated timeframe.” - Dr. Kellie Smith Research = Hope The goal of LCFA's Young Investigator grant program is to attract the best and brightest minds into lung cancer research early in their careers. This LCFA grant is big enough that they can set up their labs and gather that first big collection of data.Then, they can use this data to apply for even larger grants that may one day lead to clinical trials and hopefully new treatments. BY THE NUMBERS: Investment in Grants $200,000 >> $4 Million Kellie Smith is a shining example of LCFA's mission. Using her LCFA grants, she was generated preliminary data, made these really impactful discoveries, and then to applied for additional funding. “And, just based on my own personal experience, the LCFA Young Investigator award was the very first grant that I was ever awarded. I've been able to leverage that now into several million dollars worth of funding.”
Marco Giometto, in lizza per il prestigioso premio, è direttore del laboratorio di fluidodinamica ambientale alla Columbia University, dove si occupa di creare modelli previsionali per le città del futuro, studiandone la pianificazione urbanistica green.
Aired July 5, 1954. From 1933 to 1956 the Lone Ranger rode the radio waves. One of the most successful radio programs in history, the Lone Ranger produced over 3,000 broadcasts. Few things are more iconic in American popular culture than announcer Fred Foy reciting those lines against the opening strains of the William Tell Overture. The Lone Ranger was a western adventure show that premiered in January of 1933 on radio station WXYZ in Detroit. The show, which was aimed primarily at children, had a strong adult following as well and continued for 2,956 episodes on WXYZ, the Mutual Network and the NBC Blue/ABC networks until September 3, 1954. Repeat broadcasts continued, many in syndication by General Mills provided to select stations on electrical transcription discs, until May 25, 1956.
Hi Friends! Welcome to another episode of the diversify in path podcast. This podcast explores how investing in diversity can lead to a high return of investment in pathology and laboratory medicine by learning from the knowledge and experiences of diverse voices within in our field. My next Guest is Dr. Michael Arnold MD PhDDr. Michael A. Arnold, is the Medical Director of Anatomic Pathology at Children's Hospital Colorado, and an Associate Professor of Pathology at the University of Colorado, in Denver, Colorado. Dr. Arnold received a B.A. in molecular genetics from the University of Rochester (Rochester, NY), and completed the medical scientist training program at the University of Texas Southwestern Medical Center at Dallas, receiving his Ph.D. in Genetics and Development for his work in the laboratory of Dr. Eric N. Olson. He completed residency training in Anatomic Pathology at the University of Texas Southwestern Medical Center at Dallas and the National Cancer Institute at the National Institutes of Health. While at the National Cancer Institute, he completed a research fellowship in ultrastructural pathology and pediatric tumor pathology with Dr. Maria Tsokos. Following his research fellowship, Dr. Arnold continued at Nationwide Children's Hospital where he completed a pediatric pathology fellowship. He became a faculty member at The Ohio State University and practiced at Nationwide Children's Hospital as a staff pathologist later becoming Director of Surgical Pathology. He subsequently moved to Children's Hospital Colorado in 2019 to become the Medical Director of Anatomic Pathology, and is also currently the Pathology Informaticist for Children's Hospital Colorado. In addition to his role as Medical Director of Anatomic Pathology, Dr. Arnold practices general pediatric surgical pathology, including autopsies, gastrointestinal biopsies and pediatric cancers. He has been active in the Soft Tissue Sarcoma group in Children's Oncology Group (COG) since participating in the Young Investigator program in 2014, mentored by Dr. Erin Rudzinski, and is now a central pathology reviewer for COG rhabdomyosarcoma clinical trials. Dr. Arnold is a member of the College of American Pathologists (CAP), the United States and Canadian Academy of Pathology (USCAP), and the Society for Pediatric Pathology (SPP). He serves on the CAP Virtual Lecture Series Steering Committee, and the SPP Informatics and Communication Committee. In 2020, he was elected to serve a two-year term on the EPIC Beaker Pathology Steering Board. Dr. Arnold has authored over 60 peer reviewed manuscripts, as well as invited reviews and a book chapter on pediatric bone tumors. He lectures on various topics in pediatric pathology, including his April 2020 lecture on pediatric tumors for the CAP Virtual Lecture Series. He is also the director of the Pediatric Pathology module in PathElective.com Michael A. Arnold, MD, PhDDepartment of Pathology and Laboratory MedicineChildren's Hospital Colorado13123 East 16th Avenue, B120Aurora CO, 80045720-777-2517Michael.Arnold@ChildrensColorado.orgTwitter: @MArnold_PedPathWebsite: Michael Arnold | Children's Hospital Colorado (childrenscolorado.org)Website: PathElectivePodcast : The PathPod Podcast on Apple Podcasts| On multiple podcasting platforms
What if your lung cancer doctor could get a huge amount of information about your health, how you might respond to different treatments, and possibly even be able to tell you the best diet for your specific needs, all based on a simple test that involves no needles, no surgery, no special preparation, just a small sample… of your stool. That's the potential of studying the gut microbiome. Find out why some of LCFA's Young Investigators are so excited about including the gut microbiome in the fight against lung cancer. Guests Dr. Jarushka Naidoo Dr. Daniel Spakowicz Dr. Zoltan Loinai Dr. David Carbone, The Ohio State University Show Notes | Transcription Getting over the ick factor: Talking about poop Our bodies are teeming with microorganisms. Only 10% of the 100 trillion cells in us are human – the rest are microbes. Most of these microorganisms are found in the gastrointestinal tract with the highest concentrations found in our large intestine or gut. “So the microbiome is the collection of organisms that live on you and in you. So you have about 10 trillion human cells on your body and roughly the same number of microbes, either bacteria, viruses, fungi, and other things. They live all over, but mostly in your gut in terms of concentration. And they've got something like a hundredfold more genes than you do for being able to degrade different carbohydrates, make different molecules. And we're just starting to understand how they affect many different things, including cancer.” says Dr. Daniel Spakowicz. The immune effect of the microbiome on lung cancer may be due to specific compositions of both lung and gut microbiomes. Three of LCFA's Young Investigator grant recipients are continuing this study of gut microbiome and lung cancer, Dr. Jarushka Naidoo, Dr. Daniel Spakowicz, and Dr. Zoltan Lohinai. Gut microbiome and immunotherapy The composition of bacteria in the gut may also have a strong influence on how well advanced lung cancer patients respond to immunotherapy. Finding a positive correlation will allow doctors to use the gut microbiome as a biomarker to predict how well future patients may respond to treatment. It also raises the possibility of modifying the patient's gut bacteria before therapy with the expectation of improved effectiveness of immunotherapy. “We know that certain cells that line the gut are very important for modifying or changing our immune response. And now that we have new treatments that harness our immune response to fight cancers such as lung cancer treatments called immunotherapy, it becomes very important to understand why some immune responses are the way they are in certain patients. And can we make those immune responses stronger for some patients or change the immune responses so that perhaps patients who develop the side effects of these immune related treatments don't happen as severely or as often.” – Dr. Jarushka Naidoo The 3rd Revolution: Gut microbiomes in lung cancer treatment According to Dr. Jarushka Naidoo there have been two revolutions in lung cancer: the genomic revolution and the immunotherapy revolution. The genomic revolution happened about 10 to 15 years ago with the discovery of several genomic biomarkers. This discovery then led to several targeted therapies and understanding that lung cancer is not all created equal. And that some patients may have cancers that do well with special targeted pill therapies that may shrink those cancers. And then from there came the immunotherapy revolution, where the understanding came that maybe different lung cancers might respond to immunotherapy – using the body's immune system to fight cancer. “I think, and I hope, that our projects are the start of the microbial revolution. That we will understand that our microbiome is somehow intrinsically related to perhaps how lung cancer develops, why lung cancer grows, and how long cancer is treated. And we may be able to understand how to harness that microbial intervention to help patients and pave the way for the future.” - Dr. Jarushka Naidoo Understanding The Effects of Medications on the Gut Microbiome It often takes months or even years, to get the correct diagnosis of lung cancer. And for many people, the diagnosis happens only after medications for various respiratory ailments didn't work. These medications seem to affect the microbiome, such as antibiotics or steroids. So it's frequently treated with antibiotics that might alter the long-term outcomes of immunotherapy according to Dr. Lohinai. “So physicians should think, right, days, or weeks or months ahead of the treatment, even we don't know what treatment the patient will get by immunotherapy, but we have to see what medications we administer months before the treatment. I think it's recommended, there is no evidence, but there is a lot of data that would say that the treatment with antibiotics and steroids should be as the lowest dose. And should be lowered to the minimum to increase the outcomes of some patients because these medications can alter the outcomes of immunotherapy.” – Dr. Zoltan Lohinai The Future is Gut Microbiomes, Icky As it May Be Discovering whether a patient's gut health plays a role in determining the benefits – or, conversely, the harm – of immunotherapy treatment. Until now, there has been scant research connecting gut health with both cancer diagnoses and treatment protocols. The LCFA Young Investigator Grants are designed to help researchers look at lung cancer in new and creative ways, always with an eye toward finding better treatments that help people live longer and healthier lives. “The microbiome is certainly a very influential factor in those who get cancer, those who respond or don't respond to immunotherapy or chemotherapy…. And we don't really know the mechanism, but we're getting a whole lot better and a whole lot closer to understanding that mechanism. And it really could give us some novel insights, novel therapy targets, novel ways of improving outcomes.” – Dr. David Carbone Familiarizing the practicing clinician with the experimental methods used to generate the information that will likely impact the field of lung cancer, helping to understand gut microbiome in lung cancer treatment. As Dr. Daniel Spakowicz says, “in general, collecting somebody's poop before they start a treatment is not a commonly done practice right now, and it tends to be sort of icky to some people. And that's the essence of what we want to change.”
It's Episode 10 and season finale time. But not to worry, #LazyPod will be back after the summer break.Today on the pod is Dashun Wang! Dashun is an Associate Professor and the Founding Director of the Center for Science of Science and Innovation at Northwestern University. He works on the Science of Science, turning the scientific method upon ourselves, using amazing new datasets and tools from complexity sciences and artificial intelligence.His research has been published repeatedly in journals like Nature and Science, and has been featured in virtually all major global media outlets. Dashun is a recipient of multiple awards for his research and teaching, including Young Investigator awards, Poets & Quants Best 40 Under 40 Professors, Junior Scientific Award from the Complex Systems Society, Thinkers50 Radar List, and more. In this wide-ranging conversation, we talk about his life, career and his new book The Science of Science (1).# Timestamps[0:00:00] Sune's Intro[0:01:43] Catching up with Dashun's whirlwind career[0:36:40] We get to talking about the book # References(1) https://www.cambridge.org/core/books/science-of-science/572A745A6F97B55A263F5E86225E3F70# CreditsThe podcast has theme music by Waylon Thornton (and a little bit by me as well). WT's songs are "American Heart" and "Seven". Via freemusicarchive.org and licenced under CC BY-NC-SA. The podcast was funded in part by the Villum Foundation.
If you like this episode, check out https://otrpodcasts.com for even more classic radio shows! Learn more about your ad choices. Visit megaphone.fm/adchoices
Jessica Merlin, MD, PhD, MBA is an Associate Professor in the Division of General Internal Medicine at the University of Pittsburgh. She is board certified in internal medicine, infectious disease, palliative care, and addiction medicine. Dr. Merlin is a PhD-trained behavioral scientist and an NIH-funded clinician-investigator. Her research includes foundational work on the pathophysiology, clinical epidemiology, and behavioral management of chronic pain in people with HIV. This work has extended to management approaches to pain and opioid misuse/use disorder in individuals with serious illness in palliative care settings. Dr. Merlin has been recognized nationally for her work with three Young Investigator awards from relevant societies, an Inspirational Leader Under 40 Award from the American Academy of Hospice and Palliative Medicine, and a Cambia Foundation Sojourns Scholar Leadership Award. She is an active scientific mentor to trainees at the doctoral, post-doctoral, and junior faculty level, as is the Director of Mentoring for Pitt's Institute for Clinical Research Education as well as the Associate Program Director for Research for Pitt's Internal Medicine residency and director of the General Internal Medicine research fellowship. We all want to—and should—achieve our highest goals. But, we also want to—and should—have a good time on the journey. Today, Dr. Jessica Merlin explains how we can make difficult decisions—and assess the outcomes—in order to feel most fulfilled in our careers. There are many paths to success, so we may feel bogged down by choices, or what we fear to be “wasted time”. Dr. Merlin reassures us that pursuing opportunities in and of itself is a great way to find out what you do and don't like, and that there really are no permanent decisions in our careers in medicine. As long as we remain persistent, we will eventually get to where we want to go. After all, part of the fun of being a doctor is figuring out what that means for you, says Dr. Merlin. Pearls of Wisdom: 1. Find mentors who you want to emulate, and let their decisions influence your decisions as you progress on your career path. 2. Keep at it. The one thing that will get a project or a goal over the finish line is persistence. Persistence has value. 3. Don't put good money after bad money. Don't stick with something if you're miserable. you're allowed to take risks, reassess, and course correct. You want to reach your goals—but you want to have a good time getting there.
Plants produce a fantastic array of metabolites to defend themselves, communicate with other organisms in their environment, and attract pollinators and seed dispersers; sometimes, these metabolites can also impact human health. Our guest this week is Dr. Nadja Cech, an expert in the field of mass spectrometry and natural products. She explains how she uses this exciting tool of science to study the medical potential of herbs like kratom, goldenseal, and more. We also discuss the importance of mentorship and support of diversity and inclusion in science. *** ABOUT OUR GUEST Dr. Nadja B. Cech is Patricia A. Sullivan Distinguished Professor of Chemistry at The University of North Carolina Greensboro. She applies her expertise in mass spectrometry to solve challenging problems in natural products research. Work in the Cech group focuses on the development of strategies to understand synergy and complexity in the biological activity of botanical and fungal natural products, with a particular emphasis on the effective utilization of mass spectrometry metabolomics. Dr. Cech’s interests in this area stem from a long history of involvement in alternative medicine; her family owns and operates one of the largest medicinal herb seed companies in the country, and she spent her childhood working on their farm. Dr. Cech supervises a research group of sixteen students and postdoctoral research associates. She is the recipient of the 2011 Jack L. Beal Award for Best Paper in the Journal of Natural Products by a Young Investigator, and the 2017 Thomas Norwood Award for Undergraduate Research Mentorship. Dr. Cech is a member of the research teams for two major research initiatives funded by the National Center for Complementary and Integrative Health, the Center of Excellence for Natural Product Drug Interaction and the Center for High Content Functional Annotation of Natural Products. *** ABOUT FOODIE PHARMACOLOGY Now in Season 2 with more than seventy episodes! Tune in to explore the food-medicine continuum with Dr. Cassandra Quave as she meets with award-winning authors, chefs, scientists, farmers and experts on the connections between food and health. New episodes release every Monday! Like the show? Please leave us a rating on Apple Podcasts and share your favorite episodes with your friends! *** PODCAST DESCRIPTION: Have you ever wondered where your food comes from? Not just where it’s grown today, but where it originally popped up in the world? Have you ever bit into a delicious ripe fruit and wondered, hey – why is it this color? What’s responsible for this amazing flavor? Is this good for my health? Could it even be medicinal? Foodie Pharmacology is a science podcast built for the food curious, the flavor connoisseurs, chefs, science geeks, plant lovers and adventurous taste experimenters out in the world! Join American ethnobotanist Dr. Cassandra Quave on this adventure through history, medicine, cuisine and molecules as she explores the amazing pharmacology of our foods. *** SUBSCRIBE TO THE SHOW: Subscribe to Foodie Pharmacology on Apple Podcasts for audio and the TeachEthnobotany YouTube Channel to see full video of new episodes. You can also find more than 50 episodes of the show at https://foodiepharmacology.com/ Follow us on Twitter and Instagram at @foodiepharma or on Facebook at "Foodie Pharmacology with Cassandra Quave" *** PODCAST REVIEWS: “Professor Cassandra Quave brings quality Science to the public. She covers a wide range of topics in-depth in a seemingly effortless way. Learn from a passionate researcher, and be inspired!” – Ina on Apple Podcasts Reviews “You are what you eat — and what you listen to. Dr. Quave combines science with food, culture and history in this enjoyable, educational podcast.”--Carol on Facebook Page Reviews “We have needed this podcast for a long time. Dr. Quave's willingness to share her knowledge of plant usage and history make these podcasts interesting and helpful. The interviews from around the world are always loaded with information. Waiting on a new episode every week.”--Alan on Apple Podcasts Reviews “Great podcast about favorite foods! If you love food, you will love this podcast! Dr. Quave makes the science behind the food approachable and easy to understand. Love it!”--Liz on Apple Podcasts Reviews “Dr Quave is amazingly informative. I could listen to her talk all day. And thanks to these podcasts I can! Thank you!”-- Wendy on Facebook Page Reviews “Fascinating and entertaining! Dr. Quave is not just one of the foremost experts on the subject, she is also an incredibly gifted teacher and storyteller. I highly recommend Foodie Pharmacology to anyone with any interest in the subject.”-- John on Facebook Page Reviews “Dr. Quave is a brilliant scientist and storyteller, which makes this program both entertaining and accessible!”-- Ernest on Facebook Page Reviews “Dr. Quave is my go to source for all things Ethnobotany. Her new podcast is a great way to learn about plants and their many uses, ranging from food to medicine and so much more. I can’t wait for the newest episode!”--Paul on Apple Podcasts Reviews
Univerzitu veterinárskeho lekárstva v Košiciach absolvoval v roku 2004. Získal medzinárodný titul PhD. V rokoch 2008 – 2011 absolvoval vo svete najvyššie možné vzdelanie vo veterinárnej dermatológii na Univerzite v Edinburghu vo Veľkej Británii. Obhájil status európsky špecialista veterinárnej dermatológie. Získal tieto ocenenia: Young Investigator´s prize za najlepší výskumný abstrakt; vo Florencii získal ocenenie za najlepší vedecký referát; cenu The Ulli Runge Harms udelenú Európskou asociáciou veterinárnych dermatológov v Bruseli za najlepšiu publikáciu a prezentáciu vedeckého projektu. Viedol viac ako 100 prednášok na medzinárodných kongresoch a odborných podujatiach po celom svete. Je autorom, spoluautorom a recenzentom viacerých vedeckých, odborných a knižných publikácií. Zastrešuje dermatologický a dermatohistologický servis na pracoviskách v Žiline a Martine a jeden týždeň v mesiaci aj na špecializovaných pracoviskách vo Veľkej Británii. Moderuje Zuzana Šebestová. Tolkšou Nočná pyramída pripravuje RTVS - Slovenský rozhlas, Rádio Slovensko, SRo1. Rozhovor, interview vedie moderátor, hosť nemusí byť len „celebrita“. Respondent môže byť z najrôznejších oblastí, ako napr. umenie, kultúra, film, veda, šport, technika.
Dr. Henner Farin is a Young Investigator in the German Cancer Consortium, and a Junior Research Group Leader at the Georg-Speyer-Haus Institute for Tumor Biology and Experimental Therapy. His group uses organoids to study cell signaling in intestinal stem cells and colorectal cancer.
Legal Drugs Podcast host, Angela Stoyanovitch, walks you through her early career history that led her an interest in how drugs are brought to market. The journey or idea of a drug that is discovered in academia does not always have a linear pathway to industry. A drug in development may not end up where you may have intended it with many turns and re-routes along the way. How could a drug with indications around cancer turn into a sex behavior drug, for example? How could a cardiovascular drug turn into a sex behavior indication? Young Investigator, Angela, developed a curiosity for this unknown world into drug development and became addicted to the industry with her early work in sex behavior research.
Dr Alexandrov speaks with ecancertv at EACR 2016 about the signatures and processes exhibited by genetic mutations which result in cancer. He outlines a number of processes that can contribute to disease states, including the time-bound 'clocklike' processes and socio-environmental contributors. Dr Alexandrov considers the potential impact of bioinformatics on cancer research, and discusses how his Young Investigator award will shape his future research.
IllCon Low Lights! Describin’ Memes 3: Describin’ Condoms! Occult Gains At The Gym! The Young Investigator’s Guide To Ancient Aliens! Man Bums! Occult Star Wars Shit! A New Genre Of Dude! Travis Walton Addendum! Christians Debunking Mormonism! Weird Grating Sounds In The Sky!
Timothy Hewett, PhD Director, OSU Sports Health & Performance Institute Director of Research, OSU Sports Medicine Professor, Departments of Physiology & Cell Biology, Family Medicine, Orthopaedics and Biomedical Engineering Topics in This Podcast 1. Recent trends in ACL injury 2. How the NBA utilized Dr. Hewitt 3. Biomechanical casues of ACL injuries 4. Post injury factors 5. Screening for risk factors 6. The best exericers for reducing ACL injuries 7. Prevention and training... one in the same 8. When to starting training to prevent ACL injuries 9. Why education is the most important aspect of prevention 10. How soon is too soon to come back from an ACL injury 11. Why reinjuries happen 12. The emotional toll from an ACL injury 13. Information about the ACL Workshop: www.regonline.com/2014aclworkshop Education and Background B.A. Anthropology from the University of Cincinnati 1984 B.S. Biology the University of Cincinnati 1984 Ph.D. Department of Physiology and Biophysics, University of Cincinnati College of Medicine 1990 Postdoctoral Fellowship in Molecular Biology, Department of Pharmacology & Cell Biophysics, University of Cincinnati 1993 Experience & Interests As Director of Research, Dr. Hewett is responsible for the oversight and coordination of a multi-disciplinary research program, as well as the development of strategic OSU Sports Medicine priorities. Hewett joined Ohio State in 2010 from Cincinnati Children’s Hospital, where he served as director of the Sports Medicine Biodynamics Center. He is nationally recognized for his work in the area of knee injury prevention in female athletes. Hewett, who also serves as a tenured professor in Ohio State’s department of physiology and cell biology, completed a doctorate in physiology and biophysics from the University of Cincinnati College of Medicine, and has a post-doctoral fellowship in molecular biology. His research interests range from the molecular alteration of muscle contraction to the development of new methods for injury prevention and athletic development. Hewett is a member of the American Orthopaedic Society for Sports Medicine and the American College of Sports Medicine. He has more than 220 peer-reviewed publications, over 15,000 citations and an h-index of 70. He has authored a book and multiple book chapters. He is a permanent member of the National Institutes of Health MRS Study Section and is on the Editorial board for several medical journals. He is an international expert in the field of injury prevention, especially of ACL injuries. Dr. Hewett has received several prestigious awards, including the NCAA, Excellence in Research, Systematic Review and O’Donoghue Awards from the American Orthopedic Society for Sports Medicine, the Rose Excellence in Research Award from the American Physical Therapy Association, the Clint Thompson Award from the National Athletic Trainers Association and a Young Investigator’s Award from the American Heart Association. He has been a Keynote speaker at many national and international conferences. His work has been cited on hundreds of occasions in lay press journals, including over ten in The New York Times, as well as Wall Street Journal, USA Today, Fox News, NPR and CBS. Dr. Hewett is a member of the American Orthopedic Society for Sports Medicine, The Orthopaedic Research Society and The American Physiological Society and is a Fellow in the American College of Sports Medicine. Advising Narrative I am a Professor in the Departments of Physiology and Cell Biology, Orthopaedic Surgery, Family Medicine and Biomedical Engineering, as well as the School of Health and Rehabilitation Sciences at The Ohio State University. I have a doctorate in Physiology and Biophysics and post-doctoral fellowships in Molecular Biology and Biomechanics. I am an international leading expert in the field of injury prevention, with a special focus on ACL risk factor and prevention research. Thus far I have published over 220 peer-reviewed articles with over 15,000 citations in the medical literature, an h-index over 65 and have also authored a book and several book chapters. A permanent member of the National Institutes of Health MRS Study Section, I also serve on the Editorial board for several medical journals. My awards include the NCAA, Excellence in Research, Systematic Review and O’Donoghue Awards from the American Orthopedic Society for Sports Medicine, the Rose Excellence in Research Award from the American Physical Therapy Association, the Clint Thompson Award from the National Athletic Trainers Association and a Young Investigator’s Award from the American Heart Association. My work has been cited on hundreds of occasions in lay press journals, including over ten in The New York Times, as well as Wall Street Journal, USA Today, Fox News, NPR and CBS. My professional memberships include the American Orthopedic Society for Sports Medicine, The Orthopaedic Research Society and The American Physiological Society and I am a Fellow in the American College of Sports Medicine. Books American Orthopaedic Society for Sports Medicine. Understanding and Preventing Non-Contact ACL Injury. Champagne, IL: Human Kinetics, January 2007. 12th Annual ACL WorkshopState of the Art Prevention and Rehabilitation Program Saturday, October 11, 2014from 8 am - 5:30 pmMedical Education andResource Center (MERC)*619 Oak StreetCincinnati, OH 45229Maps and directions maybe downloaded fromwww.cincinnatichildrens.org*This is NOT held at the Main Hospital. This workshop is designed for physicians, athletic trainers, physician assistants, nurses, occupational or physical therapists, students, researchers, strength and conditioning specialists, sports medicine and orthopedic health care professionals.The ACL workshop is a day dedicated to the prevention, training, and rehabilitation of athletes who are at risk for ACL injuries. The world renowned team at the Human Performance Laboratory in the Sports Medicine Biodynamics Center will detail the latest prevention programs for female athletes. We will utilize state-of-the-art 3D motion analysis to teach athlete screening techniques. We will also teach neuromuscular training methods that focus on proper core and knee control and landing techniques. www.elitefts.com
In this podcast, 2011 winner Suzan Rooijakkers talks about her work.
In this podcast, 2009 winner Óscar Fernández-Capetillo talks more about his work and how it felt to win.
On episode #91 of the podcast This Week in Virology, Vincent, Dickson, Alan, Rich and Welkin discuss the nature, origin, and evolution of endogenous retroviruses (ERVs), and the recent finding of endogenous filovirus genomes in mammals. Host links Vincent Racaniello, Dickson Despommier, Alan Dove, Rich Condit, and Welkin Johnson Links for this episode: Welkin blogs at Small Things Considered Constructing primate phylogenies from ancient retrovirus sequences (PNAS) Filoviruses are ancient and integrated into mammalian genomes (BMC Evol Biol) Synthetic cells: Momentous breakthrough or ethical morass? (To The Point) Creation of a bacterial cell (Science) Comments on the synthetic cell (Small Things Considered) TWiV rap: T-Number Index by G-Unit (mp3) and Vincent (mp3) (thanks, Darrick and Scott!) Letters read on TWiV 91 Weekly science picks: Welkin - Advice for a Young Investigator by Santiago Ramon y Cajal Rich - How microbes define and defend us Dickson - H1N1 virus lacks 1918 virus killer protein Alan - The Xtal Set Society Vincent - Antibodies and the quest for an AIDS vaccine
Eppendorf Young Inves: In this podcast, Dr Boulton talks more about his work, how it felt to win, and following in the footsteps of his mentor Steve Jackson, who won the award himself in 1995.
Meggin gets the Young Investigator grant; idea to go canoeing this summer; the meaning of “love” in Philosophy; go run in the rain; write letters; listen to “Evening at Stu’s” tape; life with Meggin v. lone hero?
© 2020-2025 Ivy Podcast Discovery LLC
